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Abstract
Arterial stiffness is a risk factor for several cardiometabolic diseases and is caused by pathological
remodeling of the vascular extracellular matrix (ECM). Vascular smooth muscle cells (VSMCs) respond to
ECM stiffness by proliferating, migrating, and further remodeling the vascular ECM, thus contributing to
vascular disease like atherosclerosis and hypertension. VSMCs along the vasculature are highly diverse
as they arise from different embryologic origins, reside in ECMs of diverse compositions, and are exposed
to various mechanical forces. This dissertation aims to understand how ECM stiffness regulates the
transcriptional response of VSMCs from different origins, namely aortic (Ao) and coronary (Co) VSMCs.
We conducted deep sequencing of RNA from Ao and Co VSMCs grown on engineered polyacrylamide
hydrogel surfaces tuned to physiologic and pathologic stiffness. Using several bioinformatic approaches,
we compared the transcriptional landscapes in Ao and Co VSMCs by looking at whole-gene level
expression, splicing, and conservation properties, with a focus on long non-coding RNAs (lncRNAs), as
they compose a significant portion of the unexplored VSMC transcriptome. We found evidence
suggesting that the overall transcriptional response to stiffness may be conserved across species and
cell types, and that stiffness significantly dictates VSMC transcriptional identity over contributions from
embryologic origins. However, we also discovered instances of origin-specific stiffness responses in
stiffness-mediated lncRNA expression and stiffness-mediated splicing. We identified a highly correlated
network of adjacent stiffness-sensitive lncRNAs-protein coding gene pairs, which led us to experimentally
interrogate the lncRNA PACER as a regulator of stiffness-mediate expression. We surprisingly found that
PACER’s previously established regulatory pathway is absent in VSMCs. Using enrichment methods, we
identified TBX5 and show that it is a stiffness-sensitive transcription factor specific to Co VSMCs. We
also demonstrated a new role for MALAT1 as a lncRNA regulator of stiffness-dependent VSMC
proliferation and migration. Thus, this dissertation reveals many novel characteristics of the VSMC
stiffness-regulated transcriptome that may have clinical utility in understanding and managing the
pathogenesis of arterial stiffening.
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ABSTRACT
REGULATION OF THE HUMAN VASCULAR SMOOTH MUSCLE CELL TRANSCRIPTOME BY
EXTRACELLULAR MATRIX STIFFNESS
Christopher Yu
Daniel J. Rader, M.D.
Richard K. Assoian, Ph.D.

Arterial stiffness is a risk factor for several cardiometabolic diseases and is caused by
pathological remodeling of the vascular extracellular matrix (ECM). Vascular smooth
muscle cells (VSMCs) respond to ECM stiffness by proliferating, migrating, and further
remodeling the vascular ECM, thus contributing to vascular disease like atherosclerosis
and hypertension. VSMCs along the vasculature are highly diverse as they arise from
different embryologic origins, reside in ECMs of diverse compositions, and are exposed
to various mechanical forces. This dissertation aims to understand how ECM stiffness
regulates the transcriptional response of VSMCs from different origins, namely aortic
(Ao) and coronary (Co) VSMCs. We conducted deep sequencing of RNA from Ao and
Co VSMCs grown on engineered polyacrylamide hydrogel surfaces tuned to physiologic
and pathologic stiffness. Using several bioinformatic approaches, we compared the
transcriptional landscapes in Ao and Co VSMCs by looking at whole-gene level
expression, splicing, and conservation properties, with a focus on long non-coding RNAs
(lncRNAs), as they compose a significant portion of the unexplored VSMC
transcriptome. We found evidence suggesting that the overall transcriptional response to
stiffness may be conserved across species and cell types, and that stiffness significantly
dictates VSMC transcriptional identity over contributions from embryologic origins.
However, we also discovered instances of origin-specific stiffness responses in stiffnessmediated lncRNA expression and stiffness-mediated splicing. We identified a highly
vi

correlated network of adjacent stiffness-sensitive lncRNAs-protein coding gene pairs,
which led us to experimentally interrogate the lncRNA PACER as a regulator of stiffnessmediate expression. We surprisingly found that PACER’s previously established
regulatory pathway is absent in VSMCs. Using enrichment methods, we identified TBX5
and show that it is a stiffness-sensitive transcription factor specific to Co VSMCs. We
also demonstrated a new role for MALAT1 as a lncRNA regulator of stiffness-dependent
VSMC proliferation and migration. Thus, this dissertation reveals many novel
characteristics of the VSMC stiffness-regulated transcriptome that may have clinical
utility in understanding and managing the pathogenesis of arterial stiffening.
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CHAPTER 1: INTRODUCTION
Clinical Importance of Vascular Stiffening
Arterial stiffening is a long-recognized mechanical property important in cardiovascular
health. Arterial stiffness has been under investigation since the early 19th century, when
Thomas Young, who was a physician and physicist, quantified heart and arterial stiffness
and derived Young’s (elastic) modulus, a now generalizable material property1. Arterial
stiffening is a natural result of aging2–4 and is a risk factor for and consequence of
multiple cardiometabolic diseases including hypertension, atherosclerosis, coronary
artery disease, stroke, diabetes, renal disease, and all-cause cardiovascular mortality2,5–
15

. Clinically, arterial stiffness is measured indirectly using surrogate parameters such as

pulse pressure and pulse wave velocity (the gold standard), or through
pressure/diameter measurements using magnetic resonance imaging14.
Clinical Risk Factors for Arterial Stiffening
Although arterial stiffness is measurable and highly predictive of disease, there are no
therapies targeting stiffness directly and management focuses on addressing modifiable
risk factors such as lifestyle modifications16, smoking17, dyslipidemia18, diabetes and
hypertension19,20. Age and genetic factors contribute to arterial stiffness. Arterial
stiffening progresses with aging, with inflections during puberty and menopause, and
further accelerates into older age. At advanced ages, males also have a higher rate of
progression of arterial stiffening than females2–4,21. Analysis of several hundred families
in the Framingham Heart Study cohort found that arterial stiffness is a heritable trait14
and subsequent genome-wide association studies have linked several arterial stiffnessassociated traits such as pulse pressure and pulse wave velocity to single nucleotide
polymorphisms (SNP)22–24. Several monogenic disorders also result in altered vascular
1

biomechanics and premature stiffening such as mutations in FBN1 (fibrillin-1, leading to
Marfan’s syndrome)25,26, mutations in ELN (elastin, leading to Willam’s syndrome and
supravalvular aortic stenosis)27, and LMNA (lamin A, leading to progeria)28.
Mechanism of Vascular Stiffening
Tissue stiffening is a hallmark of aging and disease in many organ systems not only
arterial vasculature. In general, tissue stiffening results from cellular remodeling of the
extracellular matrix through increased deposition and crosslinking of matrix proteins, but
also through changes in matrix components. In the vasculature, both changes in matrix
stiffness, intrinsic cellular stiffness and cell contractility/tone contribute to arterial
stiffening.
Extracellular Matrix Contributions to Stiffness
During development, the vasculature is formed from a primitive endothelial plexus that
rearranges to form lumens and branches and subsequently recruits vascular smooth
muscle cells (VSMCs). These VSMCs interact with the developing vasculature by
depositing concentric layers of extracellular matrix (ECM). VSMCs secrete a myriad
collection of ECM proteins (e.g. collagens, elastin, and proteoglycans), crosslinkers (e.g.
lysyl oxidases), and matrix-metalloproteinase. The basis for vascular wall stiffness is
formed from the balance and organization of these ECM proteins (e.g. fibrillar collagens
provide load bearing tensile properties, while elastin provides elastic properties). VSMCs
only deposit and crosslink elastin during the postnatal period, thus the elastic properties
of the vascular wall are, in a sense, afforded only early in development. Through aging
and disease, elastin progressively degrades without replenishment and fibrillar collagens
are extensively deposited, leading to imbalances in the ECM and progressive
stiffening29–31.
2

Biomechanical studies suggest that the collagen/elastin ratio of the vessel wall
significantly determines arterial stiffness. At physiologic pressures/distension, the vessel
wall resides in an elastic regime dominated by elastin. As degradation occurs, the same
pressures and distension shift into a stiffer regime dominated by collagens30,31. The loss
of elastin occurs naturally during aging and is accelerated in several pathologic states.
This occurs through the upregulation of matrix-metalloproteinases (e.g. MMP-2, -9, -12)
which directly degrade elastin resulting in fragmentation, disorganization, and increased
arterial stiffness32,33. Human mutations in the elastin and fibrillin-1, a scaffold for elastin,
result in severely reduced and disorganized elastic lamina resulting in premature arterial
stiffening. In osteogenesis imperfecta, mutations in collagen I are associated with loss in
tensile properties leading to aortic root dilatation and aortic valve insufficiency, coronary
artery dissection, and aneurysms34–37.

Cellular Contributions to Stiffness
In addition to the material properties of the ECM, properties of vascular cells also
contribute significantly to overall arterial stiffening. During adulthood, VSMCs can exist in
a continuum of phenotypes between a “differentiated/contractile” state and a “dedifferentiated/synthetic” state. Under normal physiologic conditions, VSMCs are thought
to be in a predominantly contractile state where they are non-proliferative, non-secretory,
and primarily function to regulate vascular tone and blood flow. During disease, VSMCs
can de-differentiate into the synthetic state, gaining proliferative and migratory capacity
as well as secreting and crosslinking new ECM, such as fibrillar collagens and
fibronectin, but not elastin, promoting vascular wall hypertrophy, luminal narrowing, and
stiffening38.
3

Endothelial cells lining the arterial lumen serve many roles as a protective barrier and
regulator of vascular homeostasis. Endothelial cells release potent vasoactive factors
such as nitric oxide and endothelin-1 that control VSMC tone and also prevent VSMC
dedifferentiation into the synthetic phenotype39,40. During disease, endothelial
dysfunction occurs resulting in loss of the protective barrier function, leading to
inflammation and dysregulated VSMCs. Pathologic increases in vascular tone, VSMC
contractility, and thus intrinsic VSMC stiffness, contribute to total vascular wall
stiffness41,42. Endothelial and VSMC dysfunction can also result from chronic exposure to
elevated blood glucose, inflammation and renin-angiotensin signaling underlying the
association of arterial stiffness with diabetes, hypertension, and renal dysfunction19.

Lastly, arterial stiffening is both a cause and consequence of arterial stiffness. Synthetic
substrates mimicking pathologic stiffness increased endothelial cell inflammatory
markers and increased VSMC expression of matrix proteins and crosslinkers43–45.
Several in vivo models are consistent with this positive feedback mechanism of arterial
stiffening begetting more stiffening. In an obese mouse model, diet-induced arterial
stiffening measured by pulse wave velocity preceded elevated systolic blood pressures
and matrix expression9. This phenomenon was similarly seen in rat models of pulmonary
hypertension and liver fibrosis, where matrix stiffness, measured by atomic force
microscopy, preceded further matrix remodeling and fibrosis45,46.
Mechanotransduction: How Cells Sense Stiffness
The vasculature is constantly exposed to mechanical stimuli that are critical to vascular
morphogenesis and function: cyclic stretch, shear stresses, hydrostatic pressure, and
4

microenvironmental stiffness. Vascular cells sense these external stimuli through a
series of mechanotransduction events including membrane bound receptors for cellmatrix adhesions (integrins), cell-cell adhesions (cadherins), cell-fluid flow interfaces
(e.g. VEGFR2/PECAM-1/VCAM47), and stretch-sensitive receptors (e.g. ion-channels
48,49

). Cells then integrate these external stimuli through a series of downstream

signaling events leading to changes in cellular phenotype. I will focus primarily on
mechanotransduction events specific to matrix stiffness-sensing, as it is the focus of this
thesis, but the contributions of the other aforementioned mechanical forces are of equal
significance in vascular physiology and disease.

Much like how we pull on an object with more or less effort to perceive its
resistance/stiffness, early studies in the 1980-1990’s visualized and quantified cellular
traction forces50–52 and developed platforms to directly show that cells can sense an
external substrate’s resistance to intracellularly-generated traction forces53,54. Notably,
Pelham and Wang developed a collagen-coated polyacrylamide hydrogel substrate, still
extensively used in stiffness-sensing studies today, that is ideally elastic, can span
physiologic to pathologic elastic moduli, and most importantly precisely control matrix
stiffness while keeping cell-adhesion density constant. Their original study showed that
matrix stiffness controlled focal adhesion formation, and since then, several other
tunable stiffness platforms have been engineered using other natural and synthetic
polymers to understand cell stiffness-sensing and response.

Critical to stiffness-sensing is the ability of the cell to engage the ECM through integrins.
Integrins are a family of heterodimeric, transmembrane proteins that directly bind to
ECM proteins and can become activated upon engagement and with applied force. The
5

activation of integrins results in a complex cascade of intracellular signaling events, in
constant feedback, that trigger the formation and maturation of focal adhesions which
physically link the ECM to the internal actin cytoskeleton. Small RhoGTPases (e.g.
RhoA, Rac1) are activated during this process and promote further organization of the
cytoskeleton through increased actin-myosin generated forces. The forces propagate
inwards to the nucleus through the LINC (linker of nucleoskeleton and cytoskeleton)
complex but also back out toward the integrin/focal adhesion complex, resulting in a
feedback control loop of further integrin activation until cell generated forces and
resistive forces from the matrix are balanced and tensional homeostasis is achieved. At
pathologic stiffness, this process is greatly altered and tensional homeostasis can be
disrupted55–58.

The initial events in force propagation occur rapidly and do not require changes in gene
expression or new protein synthesis as the acute response utilizes already present
cellular components in a series of second messenger, phosphorylation, polymerization,
and nucleotide-exchange events. However, the initial events ultimately result in longer
time-scaled transcriptional changes that ultimately govern critical cellular processes like
proliferation and differentiation, and also induce further expression of focal adhesion and
cytoskeletal genes. These transcriptional changes occur at several levels involving
transcription factors in the immediate early response, and regulation at the epigenetic
(e.g. histone modification) and post-transcriptional level (e.g. microRNA). Several of
these processes will be discussed below.

6

Mechanotransduction: Transcriptional Response
Forces generated from stiffnesss-sensing and stretching were found to repress gene
expression through PRC2 (polycomb-repressor complex 2)-mediated histone
modifications (e.g. H3K27me3 and H3K9me2,3). These led to heterochromatin and
transcriptional silencing of several mechanosensitive genes, and this effect was
dependent on transduction through LINC complex proteins (e.g. nesprins, lamins, and
emerin)59–61. These forces not only influence chemical modifications of chromatin, but
can also physically stretch, position, and de-condense chromatin to enable transcription
62,63

. Furthermore, the nucleus itself contains mechanosensitive elements and like the

cytoskeleton, the nucleoskeleton responds by stiffening in response to applied force64.

Several mechanosensitive transcription factors have been described. MAL (MRTF-A or
MLK1) is a transcriptional co-activator that potentiates the activity of serum response
factor (SRF) to regulate expression of genes in myogenesis65. YAP/TAZ are also
transcriptional co-activators that potentiate the activity of TEAD transcription factors to
regulate proliferation and differentiation66. Both YAP/TAZ and MAL nuclear localization
are regulated by stiffness-driven actin polymerization and nucleoskeletal/cytoskeletal
tension64,67–69. NF-kB also responds to matrix stiffness70 and has been extensively
observed in response to shear stresses, requiring Rho-GTPase activity (Rac1) and
cytoskeletal organization71. Gene targets of early transcription factor activation may also
feedback to further strengthen upstream mechanotransduction events such as the
transcription of focal adhesion complex proteins72.

Matrix stiffness also regulates gene expression co- and post-transcriptionally. In breast
tumors and endothelial cells, the expression of fibronectin-EDB, VEGF-165b, and PKC7

βII isoforms are upregulated by matrix stiffness via activation of serine/arginine rich (SR)
splicing factors73. MicroRNAs (miRNAs), a class of short non-coding RNAs that target
mRNAs for degradation, also control the post-transcriptional response to stiffness. For
example, matrix stiffness increases miR-18a to reduce levels of its targets (e.g. PTEN)
contributing to malignant phenotypes in breast cancer74. miR-203, which is inhibited by
stiffness in breast epithelium, targets ROBO-1/Rac1 to regulate cell contractility and
focal adhesion complexes75.

Indeed, transcriptional regulation is a complex process. New layers of transcriptome
properties and classes of regulators are being exponentially discovered due to advances
in next-generation sequencing technologies and transcriptome-wide bioinformatic
algorithms. For example, the thousands of recently discovered long non-coding RNAs,
RNA-modifications/editing, and novel splicing patterns are only beginning to be
mechanistically implicated in critical cellular functions. As the group of studies discussed
above have yielded significant insight into mechanotranduction mechanisms, whether
and how mechanotransduction interfaces with these new transcriptome layers is
intriguing.
Specific Mechanotransduction Mechanisms in Vascular Smooth Muscle Cells
The prior section discussed mechanotransduction events elucidated from multiple
cellular systems and engineering platforms. Much of these mechanisms are intact in
VSMCs and will be discussed in detail in this section.
As briefly mentioned above, changes in ECM material properties and vascular cells
phenotypes during development and disease can dictate how various mechanical stimuli
are transmitted to and sensed by cells. For example, changes in vascular stiffness often
8

coincide with changes in vascular wall thickness, luminal diameter, and intimal barrier
permeability, resulting in altered cell exposure to cyclic wall stresses and fluid shear
stresses. Again, this section will focus mainly on the VSMC response to matrix stiffness,
but the role of these other important mechanical forces on VSMCs has been reviewed by
others76,77.
ECM-stiffness-dependent VSMC functions
Early studies using synthetic PEG-hydrogels suggested that matrix stiffness may
regulate VSMC phenotypic modulation, where increased stiffness favored the synthetic
phenotype78–80. On polyacrylamide-hydrogels, our lab and others showed that VSMCs
increased expression of ECM proteins, were more proliferative and motile on stiffer
matrices, and that VSMC migration was durotactic (i.e. migrating toward increasing
stiffness)44,45,78,81,82. Matrix stiffness also enhanced the VSMC response to plateletderived growth factor and its receptor (PDGF/PDGFR), a potent regulator of VSMC
phenotypic switching in both development and disease83. VSMC basal contractility (nonstimulated) and active contractility (vasoagonist-stimulated) were both increased at
higher stiffness substrates, and this effect was independent to changes in VSMC
differentiation state84. In vivo stiffness models, such as femoral-wire injury and
pharmacologic inhibition of lysyl oxidase, were consistent with these in vitro
findings44,45,81. These studies demonstrate that matrix stiffness regulates key VSMCspecific processes critical in arterial disease progression.
Cell-ECM interaction during VSMC stiffness-sensing
VSMC stiffness-sensing begins with integrin engagement with the underlying ECM
protein. Different integrins are activated by different ECM proteins and can affect how
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VSMCs may sense the underlying matrix stiffness, resulting in altered VSMC
phenotypes85. For example, fibronectin, which is present at low levels in normal arteries
is elevated during injury and inflammation and engages mechanosensitive integrins (e.g.
α5β1)86. Studies which independently changed fibronectin concentrations and substrate
stiffness showed that the amount of fibronectin dictated stiffness-driven VSMC
migration78. Furthermore, stiffness-mediated increases in VSMC cytoskeletal tension
and durotactic migration was greater on fibronectin-conjugated hydrogels than on those
conjugated with laminin, a “healthy” basement membrane protein typically disrupted
during disease87–90. Mechanotransduction events through VSMC cell-ECM interactions
are also influenced and balanced by cell-cell adhesions91,92.
Intracellular signaling during VSMC stiffness-sensing
Our lab recently identified a VSMC mechanosensing pathway where stiffness is
transduced through phosphorylation of FAK, p130Cas and Rac1 to regulate stiffnessmediated increases in proliferation, cytoskeletal tension, and cellular stiffening93. A
series of in vitro and in vivo studies also identified a potential positive-feedback signaling
pathway for matrix stiffening involving cyclooxygenase-2 (COX2) and lysyl oxidase
(LOX). These studies showed that matrix stiffness increases the expression of LOX,
collagens, and fibronectin. Stiffness also inhibited COX2 expression, which is necessary
to suppress stiffness-mediated expression of collagens and fibronectin44,45,94,95. At the
time of writing this dissertation, a study elucidated that the stiffness-sensitive
transcriptional co-activator, YAP/TAZ and its DNA-binding partner, TEAD, are necessary
for stiffness-mediated expression of LOX and COX-2 in VSMCs96. YAP activation also
interferes with SRF/myocardin transcriptional activity leading to repression of
contractile/differentiated phenotype genes97.
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Vascular Heterogeneity
The arterial vasculature is an extremely diverse active conduit of multiple cell types from
multiple embryonic origins experiencing multiple environmental forces.
Vascular bed mechanical property diversity
Vascular bed mechanical stimuli are extremely diverse along the length of the arterial
tree: the large diameter aorta contains multiple layers of elastic lamina experiencing
pulsatile, high pressure, high velocity flow; medium and smaller muscular arteries (e.g.
coronary and mesenteric arteries) have fewer elastic layers; arterioles experiencing less
pressures and velocities; and capillaries with laminar non-pulsatile flow are often only
lined by a single layer of mural cells. These regional differences can also be appreciated
in the observation that atherosclerotic plaques do not develop uniformly but rather sitespecifically due to differences in local blood flow properties. The compositional balance
between the different ECM proteins (e.g. collagens, elastins, proteoglycans) is also
diverse along the vascular bed, contributing to differences in overall mechanical
properties and cellular responses through differential integrin engagement30,31,98.
Vascular smooth muscle heterogeneity
VSMCs arise from various distinct embryologic origins: proepicardium (coronary
arteries), neural crest (aortic outflow tract-ascending aorta), and somatic and splanchnic
mesoderm (descending thoracic and abdominal aorta). VSMCs along the vasculature
are also phenotypically plastic and exist in a continuum of phenotypes ranging from
“contractile/differentiated” to “synthetic/proliferative” depending on stimuli. As a result of
differing embryologic origins and exposure to mechanical stimuli, regional variations in
vascular cell transcriptomes and proteomes exist98–101. For example, VSMCs isolated
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from different segments of the arterial tree vary in their expression of vasoagonist
receptors102,103, cytoskeletal proteins, and transcription factors104, and cell stiffness98.

Furthermore, VSMCs have origin-specific responses to biochemical and mechanical
stimuli: response to vasoagonists102,103, propensity to form calcifications105, proliferation,
matrix production, integrin expression, and response to TGF-beta106–108. Several studies
also show that origin-specific VSMC phenotypes and responses may be relatively stable
and maintain their properties when transplanted to different microenvironments,
suggesting that VSMC phenotype heterogeneity in vivo may be more genetically
controlled than controlled by the local microenvironment109–114. Thus, VSMC diversity
and its implication in disease is complex and covered in several comprehensive
reviews109,110,115,116.

Most of these lineage-specific VSMC differences and matrix-dependent VSMC
responses have been elucidated using predominantly non-human cell and animal
models. Recently, Cheung et. al derived VSMCs representing three distinct origins
(neural crest, somitic mesoderm and proepicardium/lateral plate mesoderm) using
human-induced pluripotent stem cells, and demonstrated VSMC-origin-specific
responses to cytokines and expression patterns of matrix remodeling proteins117.
Understanding the stiffness-dependent differences in human aortic and coronary
VSMCs, which arise from the neural crest and proepicardium, respectively, will
contribute to our understanding of differences in aortic and coronary artery disease and
will be a goal of this dissertation.
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Dissertation Goals
Given the importance of arterial stiffness as a normal consequence of aging and its
close association to several diseases, the critical role VSMCs play in responding to and
contributing to pathological matrix stiffening, and regional differences in vascular matrix
properties and in cellular embryologic origins, this dissertation aims to understand the
relative contribution of VSMC origin and matrix stiffness in dictating the VSMC
transcriptome landscape. As the in vivo milieu of matrix stiffening is complex, resulting
from many mechanical, cellular, and biochemical stimuli, this dissertation will utilize
polyacrylamide hydrogel substrates to interrogate only the consequences of stiffness.
Several unbiased approaches will be employed to characterize the VSMC stiffnesssensitive transcriptome, to identify potential transcriptional regulatory networks in the
stiffness-response, and to generate several hypotheses that will be subsequently tested.
A focus will be placed on long non-coding RNAs (discussed in detail in the following
chapters), as they compose a large portion of the unexplored VSMC transcriptome and
have been implicated in key cellular processes.
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CHAPTER 2: CHARACTERIZATION OF THE VASCULAR SMOOTH MUSCLE CELL
STIFFNESS-SENSITIVE TRANSCRIPTOME
Introduction
Recent advances in next-generation sequencing and high-throughput technology has
enabled the rapid discovery of nucleic acid sequences and modifications found in cells:
genomes, transcriptomes, epigenomes, methylomes, etc. Unlike microarrays, which only
allowed for detection of pre-defined targets, next generation sequencing allows for
unbiased discovery and quantification of both known and novel nucleic acid sequences.
This has allowed for the rapid expansion of knowledge about the human transcriptome,
the set of all RNA molecules transcribed from genomic DNA.
In the last decade, the known human transcriptome has expanded from being
predominantly composed of protein-coding transcripts to predominantly non-coding
transcripts. In early 2009, the GENCODE project reported that 47,553 human genes
were known (15,739 of these genes being non-coding RNAs). By the end of 2016,
58,219 human genes were known with about 24,355 of those being non-coding RNAs118.
While this represented an increase of 10,666 known genes, the number of known
transcripts increased even further from 132,067 to 199,325, representing newly
discovered isoforms of previously well-studied genes as well as previously unannotated
genes. While our ability to detect and define novel genes and transcripts have rapidly
evolved, the vast majority of the transcriptome is still functionally unknown.
Transcriptome landscapes and determinants of diversity
Transcriptome landscapes are extremely complex and diverse between cell-types,
tissue-types, individual organisms, and physiologic-pathologic state. Several efforts have
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utilized RNA-sequencing to define the transcriptomes of various cell types and tissues
from thousands of different humans and other organisms (GTEx, ENCODE, NIH
Roadmap Epigenomics)119–121. These multi-cellular and multi-tissue studies demonstrate
that there are multiple layers of transcriptome diversity forming the basis of cell, tissue,
and organism diversity.
In particular, transcriptome complexity arises partly from cell and tissue-type specific
gene expression (including transcription factors), alternatively spliced isoforms,
alternative transcription initiation/termination isoforms, and post-transcriptional RNA
regulators (e.g. microRNAs and editing)122. Human genomic variations, such as single
nucleotide polymorphisms (SNPs) and copy number variations (CNVs), also lead to
transcript diversity in the form of expression quantitative trait loci (eQTL), splicing
quantitative trait loci (splicing-QTL) and allelic-specific expression (ASE), where a variant
is statistically correlated to changes in gene expression pattern123.
As discussed in Chapter 1, the vasculature is heterogeneous across the body, and
different vascular beds and their VSMCs arise from different developmental origins.
Multiple studies (including GTEx and NIH Roadmaps Epigenomics)119,121 have profiled
the transcriptomes of different arteries (e.g. aorta, coronary, tibial), but these data
represent the expression not only from VSMCs but from all other vascular cells such as
endothelial cells, macrophages, and fibroblasts. Thus, while the transcriptomes of whole
vascular tissue from different regions have been interrogated, the transcriptome
landscapes of origin-specific VSMCs have not yet been explored or directly compared.
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Long non-coding RNAs
Long non-coding RNAs (LncRNAs) were among the thousands of newly identified
transcripts as a result of RNA-sequencing. LncRNAs are defined as transcripts greater
than 200 nucleotides in length which can be spliced and polyadenylated, but with no
coding potential. They contribute significantly to transcriptome diversity as lncRNA
expression patterns exhibit higher cell- and tissue-specificity than protein-coding
genes124–126. Furthermore, even if their expression is not specific, lncRNA functionality
can be cell-type specific. A large lncRNA-inhibition screen in multiple cell types identified
lncRNAs that controlled cell proliferation in only a few cell types, despite being
ubiquitously expressed in all cell types127.

LncRNAs have been implicated in biological, developmental, and pathological processes
and act through mechanisms such as chromatin modifications, cis-regulation of target
genes, and post-transcriptional regulation of mRNA processing125,128,129. Several studies
have identified VSMC-specific and VSMC-functional lncRNAs such as SENCR, lincRNAp21, MYOSLID, and SMILR130–134. These lncRNAs were found to be involved in
processes such as TGF-β signaling, actin-stress fiber formation, and regulation of
transcription factors like MAL, suggesting that lncRNAs could play a role in
mechanotransduction. To my knowledge, no lncRNA has been implicated in the cellular
response to mechanical stimuli and this chapter serves to identify lncRNAs that respond
to matrix stiffeness.
Alternative Isoforms and Splicing
The expression of alternative gene isoforms is cell and tissue specific135 and significantly
contributes to proteome diversity136. While the number of known isoforms has also grown
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exponentially, the functional consequences of most isoforms are unknown. However, in
contrast to lncRNAs, the mechanism and consequence of alternative splicing is relatively
better understood. Alternative splicing is regulated by several factors including splice-site
sequence, cis-regulatory sequences in the pre-mRNA, and expression of RNA-binding
proteins and splicing factors. Splicing can result in changes in mRNA stability,
localization, or reading-frame/translation affecting protein function137. Fibronectin (FN1)
is one of the earliest genes identified to have alternatively spliced isoforms (e.g. notably
cellular and plasma FN1) with functional consequences. With the advent of deep
sequencing, more FN1 isoforms were discovered in different developmental context.
In VSMCs, alternative splicing plays a large role in phenotype modulation. In
synthetic/de-differentiated VSMCs, the RNA-binding protein, polypyrimidine tract binding
protein (PTBP1), is upregulated, which results in exon exclusion from several
differentiated VSMCs genes138. Another RNA-binding protein, Quaking (QKI) is
upregulated in human neointimal injury and in synthetic VSMCs. QKI promotes the
expression of a Myocardin isoform that is pro-proliferative, while in differentiated
VSMCs, QKI is low and a pro-contractile Myocardin isoform is expressed139. A global
analysis VSMC splicing also showed that genes in contractile/differentiated VSMCs tend
to have more intron-retention and “poison exons” resulting in pre-mature stop codons138.
As alternative splicing appears to regulate VSMCs during phenotypic modulation and in
neointimal lesions, which are characteristically stiffer81,93, we hypothesize that matrix
stiffness alters alternative splicing events through differential regulation of splicing
factors and RNA-binding proteins. Indeed, in a gene-specific manner, a recent study
identified that matrix stiffness regulated alternative splicing of fibronectin in endothelial
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cells73. In contrast, I will approach this question using an unbiased survey of the VSMC
transcriptome in response to stiffness.
Bioinformatic pipelines for characterizing transcriptome landscapes
Although next-generation sequencing technology has been able to produce data even
more rapidly, the number of predictive tools and knowledge-databases lag behind. For
example, unlike protein coding genes, lncRNAs do not possess conserved protein
coding domains with which we can predict their biological and cellular function.
Nevertheless, several strategies have been employed to analyze large datasets and
characterize global transcriptome properties or identify specific candidate targets.
Machine-learning: Principal component analysis and hierarchical clustering
In this context, machine learning broadly refers to unbiased statistical methods to find
characteristics and insights in data. Although “machine learning” has become a buzzphrase in the last few years due to the explosion of big data, it is conceptually old and
encompasses familiar methods such as linear regression as well as new, more complex
techniques. The two most common machine-learning techniques used with
transcriptome level data are principal component analysis (PCA) and hierarchical
clustering.

PCA aims to condense high-dimensionality (>50,000 genes per sample) of
transcriptome-wide data into several “principal components”. Instead of plotting a
50,000-dimensional plot (where each axis represents one gene) which cannot be
visualized, PCA aims to represent the variation of those 50,000 dimensions in only 2 or 3
dimensions which can be easily visualized in a traditional plot (where each axis is a
principal component). These principal components (which mathematically are
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eigenvectors) are derived to represent the maximal variations in gene expression. Each
principal component is uncorrelated to all other principal components, and typically, 2 - 3
principal components encompass most of the variability in the data. Plotting samples on
a PCA plot allows visual assessment of overall similarities and differences between
samples, and whether the samples segregate into interesting groups. How samples
segregate in a PCA plot is useful for visualizing what sample characteristics is
associated with maximal gene expression variation140.

Hierarchical clustering also allows us to take high-dimensionality gene expression data
and determine “distances” between genes and/or samples, and mathematically define
groups of genes/samples. Genes that behave similarly across all samples are “close in
distance” and tend to group together, and samples whose transcriptomes behave
similarly across all genes are clustered together141.
Selecting Candidates and Predicting Function
Methods to identify novel stiffness-mediated cellular processes and potential functional
candidate genes include sequence and gene set enrichment, conservation analyses,
and correlation analyses.

In enrichment analyses, an entire transcriptome is searched for over-represented gene
signatures, or, in other words, expression patterns that occur more likely than random.
These signatures are sets of genes grouped by any characteristic. Commonly used
grouping characteristics include genes that function in a common cellular process, share
similar genomic positions, or respond to a common stimulus. This general method is
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employed in this chapter and in subsequent chapters. Specifics about this method
relevant to other chapters will be discussed in those sections.

Sequence information obtained through RNA-sequencing also enables several analysis
opportunities to identify novel transcriptome characteristics and responses, such as the
identification of novel and unannotated genes, the identification of novel splicing patterns
and transcripts, and conservation analyses. Conservation at the sequence and structural
level is often a characteristic used as an indicator that an RNA or protein contains
evolutionarily important functionality. Conservation as a predictive tool is particularly
evident in that homologous protein domains often have similar functions. In part,
microRNA conservation analyses also enabled the discovery of previously unknown
microRNA genes, the prediction of their targets, and the understanding of their
biogenesis. In comparison to protein coding genes and microRNAs, lncRNAs are
significantly less conserved. However, several lncRNAs with conserved properties (e.g.
sequence level, syntenic position, exon structure, tissue-specific expression) have been
identified with cross-species functionality142. The lncRNAs discussed in the introduction
of Chapter 3 and interrogated in Chapter 4 represent functionally conserved lncRNAs
with sequence and positional conservation.

Correlation analysis is also a particularly powerful tool in identifying networks of
functional gene relationships. Early analyses of microarray data utilized expression
pattern correlations to identify sets of tightly co-expressed genes. Some sets were later
experimentally determined to be regulated by common upstream mechanisms.
This method can also be used to infer the function of an unknown gene from the known
function of a highly-correlated gene143–146, and will be used for predicting lncRNA
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function, described more in following chapter. Correlation analyses can prioritize
potentially human disease-relevant genes from a longer list. For example, one approach
is to use observations from genome-wide association studies (GWAS). GWAS discovers
common human variants associated with human diseases and traits. Although GWAS
does not prove a causal link between a variant and a disease, it is often inferred that
genes near a GWAS variant (within the same haplotype-block) are functionally relevant
in those diseases. Indeed, several efforts have demonstrated GWAS-identified variants
to be functionally important in disease pathogenesis147. Thus, a list of candidate genes in
VSMCs, for example, could be prioritized by selecting genes that are in proximity to
GWAS-identified variants in vascular disease, as they may be significant in vascular
disease processes.

Lastly, all the outputs from these aforementioned analyses can feedback into larger
machine-learning algorithms to improve predictive power. For example, multiple datasets
have been incorporated into machine learning models to predict whether a lncRNA is a
functional growth modifier. In this method, characteristics about experimentally-validated
growth-modifying lncRNAs (e.g. specificity of expression, correlated expression to
nearby coding genes, number of exons, proximity to disease SNPs, proximity to
epigenetic marks) can be used to build a model that predicts whether an unknown
lncRNA is likely to be a growth-modifying lncRNA or not127.
Summary
In this chapter, I define and characterize the stiffness-sensitive transcriptome in human
aortic and coronary VSMCs. To achieve this, I performed deep RNA-sequencing of
VSMCs grown on physiologically soft and pathologically stiff hydrogels matrices. I used
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donor-matched aortic and coronary VSMCs such that observed differences in aortic and
coronary VSMC expression are due to the VSMC-origin and not from a confounding
donor-specific effect. This chapter establishes the similarities and differences in the
transcriptome response of aortic and coronary VSMCs to matrix stiffness in gene
expression, alternative splicing, and predicted functional consequences of transcriptome
differences.
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METHODS

Cell Culture on Stiffness-tunable Hydrogels
Donor-matched human primary aortic (Ao) and coronary (Co) artery smooth muscle cells
were cultured with smooth muscle growth medium-2 (SmGM2, Lonza) with all
supplements. Donor-matched primary VSMCs were used for the RNA-seq experiments.
Primary and hTERT-immortalized Co VSMCs (XS12C1, Lonza) were also used for
investigating MALAT1 and PACER biology in Chapter 3 and 4. VSMCs were serumstarved for 48 hours in smooth muscle basal medium (SmBM, Lonza) supplemented
with heat-inactivated fatty acid-free bovine serum albumin (1 mg/mL) before plating on
hydrogels with SmGM2.

Preparation of Polyacrylamide Hydrogels
Physiologically soft (2-4 KPa) and pathologically stiff (20-25 KPa) hydrogel matrices
coated with human fibronectin were fabricated as previously described148,149. These
elastic moduli are comparable to those reported for human atherosclerotic lesions150 and
have been shown previously to affect VSMC proliferation44,81. Furthermore, we used
fibronectin as a vascular disease relevant cell adhesion matrix, as fibronectin expression
is limited in normal healthy arteries but increased in disease such as
atherosclerosis151,152. We prepared polyacrylamide hydrogels as previously
described148,149. Briefly, acrylamide/bis-acrylamide solutions were polymerized on
glutaraldehyde-functionalized coverslips at ratios 0.3%/7.5% for pathologically stiff (20 to
25 KPa) and 0.03%/7.5% for physiologically soft (2 to 4 KPa) with acrylic acid Nhydroxysuccinimide ester. Hydrogels were then functionalized with 5 µg/mL human
fibronectin overnight and blocked with 1 mg/mL bovine serum albumin prior to cell
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seeding. Hydrogels were made on coverslips of varying sizes (50-mm for the RNAseq
study, 18-mm for validation, knockdown, and overexpression studies, and 12-mm for
EdU incorporation and migration studies).

RNA-sequencing and Bioinformatic Analysis
Four sets (biological replicates) of serum-starved donor-matched Ao and Co VSMCs
were plated at 10,000 cells/cm2 for 24 hours on 50-mm soft and stiff hydrogels (4
samples per set, total 16 samples). Cells were seeded at 10,000 cells/cm2, a relatively
low density, to minimize cell-cell interactions such that transcriptional changes resulted
primarily from cell-ECM stiffness interactions. Total RNA was isolated from cells using
RNeasy Mini Kit (QIAGEN) and TRIzol reagent following the manufacturer’s instructions.
Ribosomal RNA was depleted using Illumina Ribo-Zero Gold, and libraries were
prepared using a strand-specific TruSeq RNA library Prep kit (Illumina). Samples were
then sequenced on a HiSeq2500, 100bp paired-end (Illumina). Reads were mapped
against hg19 using STAR153. Alignment files were then filtered for high quality reads
(score >= 30) and sorted using SAMtools154. Counts per gene were determined using
HTSeq155 and human GENCODE v19 annotations118. Normalization for expression and
differential expression were done using DESeq2156. Stiffness-sensitive genes were
defined based on a false-discovery rate cut-off < 1% for each Ao and Co VSMCs. For
conservation, tissue-specificity, pathway, and correlation analyses, stiffness-sensitive
genes were determined by combining Ao and Co VSMC data with a false-discovery rate
cut-off < 1%.
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These data have been deposited in NCBI's Gene Expression Omnibus and are
accessible through GEO Series accession number GSE100081
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100081).

Expression Analysis and Transcriptome-level Clustering
We defined a gene to be expressed in cultured Ao and Co VSMCs if the average
number of normalized counts determined by DESeq2 was greater than 8. We also
assessed expression cut offs of up to 100-200 normalized counts and found similar
qualitative findings between Ao VSMCs and Co VSMCs. To assess gene expression in
whole human coronary and aortic tissues, we used expression data from GTEx
(downloaded from the GTEx portal, gtexportal.org). An RPKM > 0.7 cut off was used to
classify a gene as being expressed in each tissue type.

We defined lncRNAs as genes annotated in GENCODE with the following
transcript_type terms: lincRNA, antisense, processed_transcript, sense_intronic, and
sense_overlapping.

Principal component analysis and hierarchical clustering were performed in R using the
top 500 variant genes among all RNA-seq samples. Euclidean distances were used for
complete-linkage hierarchical clustering. Top variant genes were determined by
calculating the expression variance of each gene across all samples (Ao and Co VSMCs
cultured on both soft and stiff). Heatmaps were generated in R using the pheatmap
package. Venn diagrams were generated in R using the VennDiagrams package.

Conservation and Tissue Specificity Analysis
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To assess the sequence conservation of stiffness-sensitive v. insensitive genes, we
used the pre-computer PhastCons 46-way (vertebrate) scores that were downloaded
from the UCSC browser (http://genome.ucsc.edu/). Scores were calculated for each
exon per gene accounting for the length of each exon. Cumulative distributions were
determined and plotted for stiffness-sensitive and stiffness-insensitive genes. A
Kolmogorov–Smirnov test was performed to determine statistical significance between
distributions.

For each stiffness-sensitive and insensitive gene identified in Ao and Co VSMCs, we
counted the number of tissues where that gene had a median RPKM > 0.7 in the GTEx
database. Cumulative distribution functions of the number of tissues expressing VSMCidentified (in this study) stiffness-sensitive v. insensitive genes were generated. A
Kolmogorov–Smirnov test was performed to determine statistical significance between
these distributions.

Pathway Analysis and Correlation Analysis
Differential gene expression lists generated by DESeq2 using combined Ao and Co
VSMC expression values were uploaded into Ingenuity Pathway Analysis (QIAGEN). A
FDR < 1e-7 and an absolute LogFC > 1 were used to select analysis-ready molecules.
Top enriched “categories” and “functions” were assessed. We identified lncRNAs
attributed to each significant category or function. These enriched lncRNAs were then
ranked based on the number of occurrences within the significant category or functions.

KEGG and REACTOME terms were enriched using the Gene Set Enrichment Analysis
tool (GSEA, Broad Institute)157. For each VSMC cell type, genes were ordered based on
26

their FDR values resulting from differential expression analysis (DESeq2). This ordered
list was used as an input for GSEA. Significant term enrichment was determined using
an FDR <1% for KEGG terms or PWER < 1% for REACTOME terms.

To characterize the transcriptome landscape locally to each lncRNA, Spearman’s
correlation coefficients and p-values were calculated for all pairs of genes within the
same chromosomes using the combined Ao and Co VSMC expression data. We
focused on all lncRNAs and plotted correlation scores vs. distance from the lncRNA in
base pairs. To determine statistically significant correlated lncRNA-gene pairs, we
corrected for multiple hypothesis testing (Bonferroni, e.g. p-value threshold for
significance was p < 1e-5 for all lncRNA-gene pairs within 50kb from the lncRNA, plotted
as red dots). Histogram plots of significant correlations were compared between
stiffness-sensitive lncRNAs and an equivalent number of the most variant (calculated by
variance across all Ao and Co VSMCs) stiffness-insensitive lncRNAs.

To identify putative functional stiffness-sensitive lncRNA-protein coding gene pairs, we
ranked the top stiffness-sensitive lncRNAs (fold change > 2) that were significantly
correlated with a stiffness-sensitive protein coding gene (with fold change > 2) with an
association p-value < 1e-3 and within 100kb away from each other. The top stiffnesssensitive lncRNA-protein coding gene pairs are presented in Table 5.

Differential Splicing Analysis using MAJIQ
Fasta files and STAR-aligned files from the RNA-seq experiment were used as inputs
into MAJIQ to quantify the PSI (percent spliced in), which is the relative abundance of
each local splice variations (LSV, or splice junction) in each gene158. For each LSV, the
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delta PSI (change in PSI between soft and stiff matrices) threshold cutoff was set at 20%
(E(dPSI) > 0.2). MAJIQ and VOILA were run for Co VSMC and Ao VSMC separately.

Association of Stiffness-sensitive Splicing to Cardiovascular GWAS traits.
Differentially spliced genes as defined above were associated with SNP variants in the
NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) Version 1.0. The genomic coordinate
for each SNP was translated into hg19 coordinates using the track: “GWAS catalog”,
table: “gwasCatalog” from the UCSC genome table browser. Only SNPs relevant to
vascular disease and genome-wide significant (p < 5 x10-8) were used for analysis. The
list of relevant vascular diseases used in this analysis is in Appendix 1. Only genes
within 50kB of the disease-associated SNP were considered as “associated” to stiffnesssensitive genes.
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RESULTS
The Landscape of the Stiffness-sensitive Transcriptome of Co and Ao VSMCs
(Gene Expression Level)
We implemented deep RNA-sequencing to comprehensively define gene expression in
donor-matched aortic (Ao) and coronary (Co) vascular smooth muscle cells (VSMCs) in
response to physiologically soft and pathologically stiff hydrogel matrices (Figure 1).
Using GENCODE annotations, we identified a total of 17,716 genes expressed in either
Ao or Co VSMCs and in either soft or stiff conditions (Figure 2A); 93.2% were expressed
in both cell lineages (DESeq2 mean normalized counts > 8). Of all expressed genes,
13,574 were protein-coding genes, and 2,379 were long non-coding RNAs. Further
inspection revealed protein-coding genes are more commonly expressed in both
lineages of VSMCs than lncRNAs (95.7% v 82.9%). These proportions are consistent
with expression data obtained from whole human coronary and aortic tissues in the
GTEx database (Figure 3). The degree of uniquely expressed lncRNAs (17.1%) and
protein coding genes (4.3%) may reflect the unique developmental origin and
transcriptome program of Ao and Co VSMCs.

Principal component analysis of the top 500 most variant genes revealed that matrix
stiffness is a major contributor to expression differences (as is it most segregated by the
first principal component) and accounts for approximately 54% of variation in gene
expression. VSMC origin is also a major contributor accounting for about 36% of the
expression variance (Figure 2B). Consistent with this analysis, unsupervised hierarchical
clustering with the 500 most variant genes revealed that Ao and Co VSMCs cultured on
the same matrix stiffness clustered together (Figure 2C). This clustering is similar when
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clustering based only on protein coding genes or even lncRNAs despite their reduced
overlap in expression between Ao and Co VSMCs (Figure 2D).
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Figure 1. Experimental and computational flow chart for interrogating the VSMC stiffnessmediated transcriptome.
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Figure 2. Expression Landscape of Aortic and Coronary VSMCs
(A) Venn Diagrams depicting the overlap of expressed genes (defined as normalized counts > 8)
in Ao VSMCs and Co VSMCs by type. (B) Principal component analysis plot of the first two
principal components using the top 500 variant genes (all genes). (C) Hierarchical clustering of all
Ao and Co VSMC samples using the top 500 variant genes (all genes). (D) Principal component
analysis and hierarchical clustering of all Ao and Co VSMC samples by either the top 500 variant
protein coding genes or lncRNA genes
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Figure 3. Expression Landscape of Whole Aortic and Coronary Artery Tissue from GTEx
Database
(A) Comparison of expression overlap of human aortic tissue and coronary artery tissue from
GTEx. Venn diagrams depicting the overlap of expressed genes (defined as RPKM > 0.7) in
aortic and coronary tissue expression data.
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Global Characteristics of Stiffness-sensitive Gene Expression of lncRNAs and
Protein-coding Genes
We conducted pair-wise differential expression analysis and found that a total of 5818
genes are differentially expressed by matrix stiffness (stiffness-sensitive, SS) in either
Ao or Co VSMCs (FDR<1%) (Figure 4A,Figure 4B). From here on, we will define SS
genes as the following: Origin-Specific (OS-SS) are genes identified as SS in only Ao
OR Co VSMCs; Origin-Non-Specific (ONS-SS) are genes identified as SS in both Ao
AND Co VSMCs; ALL-SS are genes identified as SS in either Ao OR Co VSMC (see
Figure 4B for a graphical representation).

Of the genes identified as stiffness-sensitive, 3098 (53.2%) are ONS-SS, with 2842
being protein coding genes and 157 being lncRNAs. Interestingly, lncRNAs are more
likely to be OS-SS than protein coding genes. That is, 57% (206/363) of ALL-SS
lncRNAs are OS-SS, compared to only 45% (2377/5219) of ALL-SS protein coding
genes are OS-SS (Figure 4C).

We also found that if a gene was SS in either VSMC (ALL-SS), that gene was more
likely to be expressed (DESeq2 normalized count > 8) in both VSMC lineages than a
gene that was stiffness-insensitive (Figure 5). For example, 93% of ALL-SS lncRNAS
are expressed in both VSMCs and 88% of OS-SS lncRNAs are expressed in both
VSMCs. This is in comparison to stiffness-insensitive lncRNAs, where only 83% of
stiffness-insensitive lncRNAs are expressed in both VSMCs. This is similar, but to a
lesser degree, for protein coding genes. 98% of ALL-SS protein-coding genes are
expressed in both VSMCs and 97% of OS-SS protein coding genes are expressed in
both VSMCs, while 96% of stiffness insensitive protein coding genes are expressed in
34

both VSMCs (Figure 5A, Figure 5B). We also analyzed these percentages over different
DESeq2 count thresholds (used to define if a gene was expressed) and found that these
qualitative findings hold true across a large range of cut-off values (Figure 5C). Taken
together, these observations suggest that genes classified as SS tend to be expressed
in an origin non-specific manner (found to be expressed in both VSMCs), and that the
SS transcriptome may be conserved. Conversely stated, stiffness-insensitive genes
were more likely to be expressed in an VSMC-origin specific manner.

Indeed, we find that SS genes were significantly more conserved at sequence level
using phastCons scores (Figure 6, Left). SS protein coding genes and lncRNAs both
exhibited increased conservation over stiffness-insensitive genes. Furthermore, using
data from the GTEx project, we find that SS genes are expressed (cutoff of RPKM>0.7)
in more tissue types than stiffness-insensitive genes (Figure 6, Right). The SS
transcriptome appears to be a conserved cellular response, which suggests that SS
lncRNAs, by way of their increased conservation across species and tissue-types, may
control stiffness-dependent functions.
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Figure 4. Heatmap of the VSMC Stiffness-sensitive Gene Expression
(A) Heatmap of stiffness-sensitive genes (FDR < 0.01) in both Co VSMC and Ao VSMCs.
Heatmap colors correspond to log2 (normalized counts). (B) Legend for diagram of origin-specific
stiffness-sensitive genes (OS-SS), origin-non-specific stiffness-sensitive genes (ONS-SS), or
stiffness-sensitive genes in either Ao or Co VSMCs (ALL-SS). (C) Venn diagrams depicting the
overlap in stiffness-sensitive genes in Ao and Co VSMCs.
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Figure 5. Cell-specific expression of stiffness-sensitive genes
(A) Venn diagrams depicting the number of cell-specific stiffness-sensitive genes (by FDR<0.01)
that are cell-specific-expressed (by normalized count > 8) or expressed in both Ao and Co
VSMCs. (B) Overlap of expressed stiffness-sensitive genes (identified in either Ao or Co VSMCs)
in Ao or Co VSMCs. 93% of ALL-SS lncRNAs (identified as stiffness-sensitive in either Ao or Co
VSMCs) are expressed (normalized count > 8) in both Ao and Co VSMCs compared to 83% of
stiffness-insensitive lncRNAs. More stiffness-sensitive genes are expressed in both cell types
than stiffness-insensitive genes. (C) Percent overlap as in panel B but comparing stiffnesssensitive vs. all genes per subtype over various expression cut-offs (DESeq2 normalized count
from 0 – 200).
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Figure 6. Sequence Conservation and Tissue Expression Analysis of the VSMC StiffnessSensitive Genes
Cumulative distributions of conservation (phastCons) scores and tissue expression (GTEx) of
stiffness-sensitive v. stiffness-insensitive genes. In-set figure of lncRNA distribution shows
zoomed-in distribution at conservation scores 0 to 0.15. A right-shifted cumulative distribution
demonstrates higher conservation or expression in more tissues. P-values determined using a
Kolmogorov–Smirnov test.
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To identify putative stiffness-dependent functions common and unique to Aortic and
Coronary VSMCs, we performed unbiased enrichment analyses using Gene Set
Enrichment Analysis157 and Ingenuity Pathway Analysis (QIAGEN) (Figure 7). Both
methods identified several highly enriched cellular processes in both Ao and Co VSMCs:
cell cycle, growth, death, motility, morphology, RNA post-transcriptional modifications
(such as splicing).
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Figure 7. Predicted Stiffness-dependent cellular functions
(A) Venn Diagrams representing the common and unique gene sets enriched from the KEGG and
REACTOME databases. (B) Selected common KEGG and REACTOME pathways enriched in
both Ao and Co VSMCs. The full list appears in the Appendix. (C) Top categorical pathways
enriched in shared stiffness-sensitive genes in Ao and Co VSMCs using Ingenuity Pathway
Analysis
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The Landscape of the Stiffness-sensitive Splicing in Co and Ao VSMCs (Isoform
Level)
Another level of transcriptome diversity and regulation is alternative splicing events.
Splicing was a highly predicted process regulated by stiffness in both Ao and Co VSMCs
(Figure 5, Terms: KEGG-Spliceosome, Reactome-mRNA_Splicing, Ingenuity-RNA posttranscriptional modifications). Within these gene sets were stiffness-sensitive RNAbinding proteins and splicing factors such as PTBP1 (upregulated by stiffness (Ao, Co)
log2FC (-0.55, -0.6), FDR (3e-3, 8e-4)), previously identified to regulate splicing in VSMC
phenotypic modulation. To assess splicing events in response to stiffness, we used the
MAJIQ (Modeling Alternative Junction Inclusion Quantification) algorithm suite158 to
detect and quantify local splice variations (or splicing events). In contrast to stiffnesssensitive gene expression, stiffness-sensitive splicing was less similar between Ao and
Co VSMCs. Only 61 genes (12.8%) were differentially spliced in both Ao and Co VSMCs
(Figure 8A). About one-third (23) of these 61 genes were also differentially expressed at
the gene level in both VSMCs, while another one-third (23) of these genes were only
differentially spliced without change in their gene-level expression (Figure 8B). Thus,
alternative splicing appears to be a more origin-specific layer of the stiffness-sensitive
transcriptome than gene level expression.
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Figure 8. Stiffness-sensitive splicing in Co and Ao VSMCs
(A) Venn Diagram depicting the number of genes differentially spliced by stiffness in Ao and Co
VSMCs. A gene was considered differentially spliced by stiffness if that gene had a local splice
variation (LSV or splice junction) with > 20% differential exon/intron inclusion (delta PSI). (B)
Four-way Venn diagram comparing differentially expressed vs. differentially spliced genes in Ao
and Co VSMCs.
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Global properties of differentially spliced genes
Using the Database for Annotation, Visualization and Integrated Discovery (DAVID)
tool159,160, we looked for properties annotated to differentially spliced genes in both Ao
and Co VSMCs. Table 1 depicts the list of enriched annotations and terms associated
with differentially spliced genes. Surprisingly, a significant number of differentially spliced
genes are annotated as “phosphoproteins” in the uniprot database (35 out of 61).
Several terms are also associated to known mechanotransduction components:
cytoskeleton and actin-binding proteins. Four genes containing SH3 domains were also
enriched in this analysis (Table 2). SH3 domains (Src homology 3 domains) are protein
domains often found in signal transduction proteins allowing for protein-protein
interactions especially in cytoskeletal and small GTPase signaling pathways161,162.
Whether these four genes and their SH3 domains are involved in stiffness-dependent
downstream effects is unknown.
Thus, we further analyzed how the differential splicing events in these four genes may
alter their properties. Surprisingly, the stiffness-mediated splicing events in these four
genes directly involved their SH3 domains (Figure 9). We found that matrix stiffness in 3
out of 4 of these genes (SASH1, MACF1, and MIA3) increased the relative abundance
of exon junctions consistent with transcripts lacking SH3 domains (Figure 9 A, B, D).
And at the gene expression level, both MACF1 [(Ao,Co), log2FC (0.77, 0.9), FDR (9e-6,
4e-6)] and MIA3 [(Ao,Co), log2FC (1.1, 1.3), FDR (9e-10, 2e-10)] were down-regulated
by stiffness. In contrast, SH3PXD2A (Figure 9 B) had a more complex local splicing
pattern with multiple acceptor exons and 1 common splice donor exon. For SH3PXD2A,
stiffness increased the relative abundance of transcripts containing 3-4 SH3 domains
(Figure 9 C, green junction), and decreased the relative abundance of a novel junction
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not annotated in the GENCODE annotations (Figure 9 C, red junction). This novel
junction is predicted to cause a frameshift and a premature stop codon resulting in a
transcript with only 1 partial SH3 domain. Taken together, stiffness alters the relative
abundance of SH3 domains in transcripts of these 4 genes and may affect contribute to
stiffness-mediate signal transduction.
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Benjamini
Gene Count P-Value Corrected p-Value

Category

Term

UP_KEYWORDS

Alternative splicing

43

0.000027

0.0037

UP_KEYWORDS

Phosphoprotein

35

0.00033

0.023

UP_KEYWORDS

Cytoplasm

23

0.0026

0.085

UP_KEYWORDS

Cytoskeleton

10

0.0023

0.1

UP_KEYWORDS

Acetylation

18

0.0042

0.11

UP_KEYWORDS

Actin-binding

5

0.0054

0.12

UP_KEYWORDS

Coiled coil

16

0.0081

0.15

UP_KEYWORDS

SH3 domain

4

0.018

0.27

UP_KEYWORDS

Glycolysis

2

0.077

0.57

UP_KEYWORDS

Isopeptide bond

7

0.07

0.6

UP_KEYWORDS

Tumor suppressor

3

0.076

0.6

UP_KEYWORDS

Nucleus

20

0.061

0.62

UP_KEYWORDS

Ubl conjugation

9

0.069

0.63

UP_SEQ_FEATURE

splice variant

36

0.000027

0.0083

UP_SEQ_FEATURE

compositionally biased region:Poly-Ser

6

0.01

0.65

UP_SEQ_FEATURE

compositionally biased region:Poly-Gln

4

0.0077

0.7

UP_SEQ_FEATURE

compositionally biased region:Pro-rich

7

0.04

0.96

UP_SEQ_FEATURE

short sequence motif:Nuclear localization signal

4

0.06

0.98

UP_SEQ_FEATURE

domain:SH3

3

0.076

0.98

Table 1. Enriched annotations of differentially spliced genes
Enriched uniprot terms associated with the 61 commonly differentially spliced genes in both Ao
and Co VSMCs. Categories are derived from the uniprot database (uniprot.org). The number of
genes associated to each term is denoted under “gene count”.

Gene Symbol

Gene Name

MACF1

microtubule-actin crosslinking factor 1

MIA3

MIA family member 3, ER export factor

SASH1

SAM and SH3 domain containing 1

SH3PXD2A

SH3 and PX domains 2A

Table 2. Differentially spliced genes with SH3 domains
Genes associated with the uniprot term SH3 domain and are differentially spliced by stiffness in
either Ao or Co VSMCs
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Figure 9. Schematic diagrams of differentially spliced genes containing SH3 domains
(Continued below)
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Figure 9 (Continued). MAJIQ Local Splice Variation (LSV) Diagrams depict the splicing junctions
found to be stiffness-sensitive. The yellow square represents an exon that acts as the common
splice acceptor/donor. Red, blue and green squares represent exons that act as the differentially
included or excluded exon. The percent spliced in (PSI) is the relative abundance of each junction
in the LSV. The horizontal bars represent the delta PSI of each junction on stiff or soft matrices.
Below each LSV diagram is a track view of each gene’s structure from the GENCODE V19
Comprehensive Set Track from UCSC Genome Browser. Each isoform and the exon-intron
structure is represented in black. The dotted red line represents where an SH3 domain is
encoded. Red, blue, green and yellow highlighted regions correspond to the same exon squares
in the LSV diagram. Junctions are also depicted above the gene track.
(A) Schematic for SASH1. The red junction, increased relative abundance by stiffness, represents
an isoform lacking the SH3 domain.
(B) Schematic for MACF1. The blue junction, increased relative abundance by stiffness,
represents an isoform lacking the SH3 domain.
(C) Schematic for SH3PXD2A. The green junction, increased relative abundance by stiffness,
represents isoforms containing 4 entire predicted SH3 domains. The red junction, decreased in
relative abundance by stiffness is not represented in any of the annotated isoforms and may be a
novel junction. This junction would result in a premature stop codon resulting in a transcript
containing 1 partial SH3 domain.
(D) Schematic for MIA3. The blue junction, increased in relative abundance by stiffness
represents an isoform lacking the SH3 domain.

Association of stiffness-sensitive spliced genes with cardiovascular diseaseGWAS variants
Several GWAS variants have been associated with alternative splice sites and events,
termed splicing quantitative trait loci (splicing-QTL)163. We asked whether any of the 61
commonly spliced genes were associated with GWAS variants of cardiovascular traits
relevant to aortic disease, coronary disease, or vascular stiffening. Only 2 of the 61
stiffness-spliced genes were associated with GWAS-identified loci: FURIN-FES and
MIA3. Variants near FES and MIA3 were associated with coronary artery disease,
myocardial infarction, and blood pressure.
As described previously, the relative abundance of MIA3 containing SH3 domains is
reduced by stiffness. Three disease-associated variants are found within the MIA3 gene;
one variant (rs35700460) is located in the intron directly upstream of the isoform lacking
the SH3 domain, and two (rs17465637 and rs67180937) are located further downstream
47

near constitutive exons (Figure 10 A). The risk-alleles for all three SNPs are eQTLs and
associated with reduced MIA3 gene expression (in aortic but not coronary tissue), but
none were splicing-QTLs in the GTEx database (Table 3).
Two variants were also identified in the FURIN-FES locus (Figure 10 B). One variant
(rs2521501) located in an intronic region of FES, was associated with blood pressure (a
consequence and risk factor of vascular matrix stiffening). This variant was also
identified in a myocardial infarction GWAS, but its p-value (2e-7) was just under the
genome-wide significance threshold (p < 5e-8). The second variant (rs17514846) is
located in an intronic region of FURIN and is associated with coronary artery disease but
also with a p-value (3e-7) just under the genome-wide significance threshold. Whether
both of these variants are linked to changes in FURIN and/or FES activity is unknown.
The FES intronic variant (rs2521501) is an eQTL for FES, with the risk-allele associated
with reduced expression (in aorta and tibial artery but not coronary tissue), but not a
splicing-QTL in the GTEx database (Table 3).
As FES was differentially spliced by stiffness and intronic variants in FES were
associated with several cardiovascular traits, we further investigated the splicing pattern
in FES. Surprisingly, matrix stiffness increased the relative abundance of exon junctions
consistent with FES transcripts lacking an SH2 domain (Figure 10 B, blue junction). SH2
(Src homology 2) domains, like SH3 domains, are critical in protein-protein interactions
and signal transduction, but specifically allow binding to phosphorylated tyrosine
residues161,162. Taken together, these observations suggest that stiffness-mediated
splicing of FES and MIA3 could be a mechanism contributing to vascular-related
diseases.
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Gene Symbol

SNP

P-Value

Effect Size

Tissue

MIA3
MIA3
MIA3
FES
FES

rs67180937
rs35700460
rs17465637
rs2521501
rs2521501

1.3E-06
3.9E-06
1.3E-06
2.6E-10
4.3E-08

-0.30
-0.28
-0.29
-0.34
-0.21

Artery - Aorta
Artery - Aorta
Artery - Aorta
Artery - Aorta
Artery - Tibial

Table 3. Expression quantitative trait loci (eQTL) for cardiovascular disease-related GWAS
variants associated with stiffness-sensitive genes.
These data are from the GTEx (gtexportal.org) database. eQTLs were searched in aorta,
coronary artery, and tibial artery tissues. Effect sizes < 0 correspond to reduced expression
associated with the risk-allele.
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Figure 10. Schematic diagrams of stiffness-sensitive spliced genes and relationship to
cardiovascular trait GWAS-identified variants.
(continued below)
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Figure 10 (Continued). For each locus (A) and (B), the table of GWAS-identified variants (SNP)
and the associated disease trait is listed. The reference for the discovery of each variant is listed:
23
164
164
165
Wain LV , Ehret GB , Schunkert H , Nikpay M . The location and type of each variant is
listed and depicted each schematic (green arrow).
(A) Schematic for the MIA3 Locus. Table of the GWAS-identified traits in the MIA3 locus. The
blue junction, increased in relative abundance by stiffness represents an isoform lacking the SH3
domain.
(B) Schematic for the FURIN-FES Locus. Table of the GWAS-identified traits in the FURIN-FES
locus. The blue junction, increased in relative abundance by stiffness represents an isoform
lacking the SH2 domain.

DISCUSSION
Although vascular stiffness has been identified as an important risk factor for
cardiovascular disease, our understanding of how vascular stiffness alters vascular
cellular behavior is incomplete. This study provides the first comprehensive analysis, at
the gene-level and isoform-level, comparing the stiffness-sensitive transcriptome in
human Ao and Co VSMCs with a focus on lncRNAs. We found that Ao and Co VSMC
transcriptome profiles are significantly dictated by matrix stiffness, and that stiffnesssensitive genes (whether protein coding or lncRNA) are more commonly co-expressed in
Ao and Co VSMCs compared to stiffness-insensitive genes. We also found that VSMC
stiffness-sensitive genes are overall more species conserved and expressed in more
tissue types than stiffness-insensitive genes. Furthermore, we observed that stiffnesssensitive lncRNAs may be more origin-specific response (between Ao and Co VSMCs)
than stiffness-sensitive protein coding genes.

We find that ECM stiffness significantly dictates the transcriptomic identity of Ao and Co
VSMCs. Prior studies have suggested that VSMC from different embryologic origins are
rather phenotypically stable even when transplanted into disparate vascular
microenvironments98,110,111; however, these transplantation studies are uncontrolled for
any particular microenvironmental parameter. By using donor-matched Ao and Co
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VSMCs, any differences we observe in the transcriptome of Ao and Co VSMCs arise
from contributions from embryologic lineage programs or the effect of ECM stiffness. Our
clustering analysis suggests that ECM stiffness may override the embryologic-origin
contributions to the transcriptome; the transcriptome of Co VSMCs/stiff matrix is more
similar to Ao VSMCs/stiff matrix than Co VSMCs/soft matrix. However, we also did
identify the presence of OS-SS genes and observed that SS lncRNAs tended to be more
origin-specific than SS protein coding genes.

Several studies support this notion that ECM stiffness may significantly dictate cell
transcriptomic identity. ECM stiffness and other mechanical parameters are critical in
tissue and organ development166. Early studies demonstrated that ECM stiffness can
dictate stem cell fate and that different stiffness can promote different lineages167–170.
ECM stiffness has also been shown to alter nuclear mechanics, chromatin organization
and the activity of a variety of ubiquitous transcription factors in multiple cell types,
leading to global transcription changes56,60,171–173.

In further support of this idea, we found that ALL-SS (identified as stiffness-sensitive in
either Ao or Co VSMCs) tended to be expressed in both VSMC lineages and across
more tissue types than stiffness-insensitive genes. These stiffness-sensitive genes were
also more conserved across species at the sequence level. This suggests that the
stiffness-sensitive gene set may represent a critical response module across many cell
types and regulate cell-ubiquitous processes, as predicted by enrichment analyses.
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Implications of Splicing Observations
At the transcript/isoform-specific level, we found that many splicing regulatory genes
were stiffness-sensitive and an unbiased analysis of junctional reads altered by stiffness
yielded many potentially stiffness-sensitive splicing events. We found that the stiffnesssensitive splicing was highly origin-specific with only a 13% overlap compared to
stiffness-sensitive gene level expression (53% overlap).
The splicing of cytoskeletal proteins is a significant process in development and disease
of cardiac, skeletal, and smooth muscle tissues137. Rather unsurprisingly, we found that
cytoskeletal and cytoskeletal associated proteins were enriched in stiffness-spliced
genes identified in both Ao and Co VSMC. However, rather unexpectedly, we found that
SH3 domain containing genes were also enriched, and that the stiffness-sensitive
splicing events are predicted to result in inclusion or exclusion of these domains. Though
not shown above, several SH3 domain containing genes were also significantly spliced
by stiffness in a VSMC origin-specific manner. RT-PCR analyses will be required to
validate these RNA-seq findings.
There is evidence that SH3 domains are important in VSMC-specific stiffness-sensing.
For example, the SH3 domain in p130Cas, a key mechanotransduction protein, is
necessary for transducing matrix stiffness into VSMC proliferation and intracellular
stiffening93. As stiffness-dependent activation of p130Cas is phosphorylation-mediated,
we did not necessarily expect nor find stiffness-mediated splicing of p130Cas. However,
we inspected each of the SH3 domain containing genes and found that stiffness is
predicted to repress inclusion of the SH3 domain in 3 genes (SASH1, MACF1, and
MIA3) and include multiple SH3 domains in 1 gene (SH3PXD2A).
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MIA3 (melanoma inhibitor activity member 3, a.k.a. TANGO1) is an endoplasmic
reticulum resident transmembrane protein that functions in the packaging and export of
several collagens (I, II, III, IV, VII, and IX), but not fibronectin, within large vesicles. The
SH3 domain in MIA3 binds directly to collagen VII alpha-1 but not collagen I, despite
global defects in collagen I deposition in MIA3-knockout mice174,175. Three intronic SNPs
within MIA3 are associated with increased risk for coronary artery disease and
myocardial infarction. How these SNPs contribute to this increased risk is unknown.
However, each SNP is a significant eQTL for MIA3 gene expression in aortic but not
coronary tissues (GTEx database). The risk-alleles for all three SNPs are associated
with reduced MIA3 expression. We also found that stiffness reduced MIA3 gene level
expression, with a disproportionate reduction in SH3-containing MIA3 transcripts. One
SNP (rs35700460) is located upstream to the alternative start exon of the SH3-lacking
MIA3 isoform, and perhaps contributes to usage of an alternative promoter. Thus, we
could speculate that arterial stiffening and MIA3 locus SNPs may additively contribute to
CAD and MI by reducing MIA3 expression, resulting in an abnormal vascular ECM.
Except for MIA3, the specific role and binding partners of the SH3 domain in the
remaining 3 genes are relatively unknown, but their overall function may suggest their
role in stiffness-sensing. MACF1 (Microtubule actin crosslinking factor 1 or a.k.a. ACF7)
coordinates microtubule alignment along F-actin at focal adhesions. MACF1-knockout
keratinocytes exhibited larger focal adhesions and impaired migration without changes in
phosphorylated FAK, or levels of active RhoA, Rac1, and Cdc42176. Perhaps the SH3
domain in MACF1 is important for its association with the actin cytoskeleton and may
partially control stiffness-mediated migration.
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SH3PXD2A (SH3 and PX domains 2A, a.k.a. TKS5, Tyr kinase substrate with five SH3
domains), is a critical and specific podosome/invadopodia adaptor protein required for
cell invasion177. Podosome/invadopodia formation is upregulated by ECM stiffness in
breast epithelium178 and reports have found SH3PXD2A containing podosome in VSMCs
in vitro and in vivo179. Perhaps the stiffness-mediated inclusion (soft substrateassociated truncation) of SH3 domains in SH3PXD2A serves to increase invasiveness of
VSMCs during vascular disease. Lastly, almost nothing is known about SASH1 (SAM
and SH3 domain containing protein 1), other than its expression has been linked to
smoking and atherosclerosis180.
Lastly, we found matrix stiffness was predicted to splice out the SH2 domain of FES.
FES is a non-receptor protein tyrosine kinase implicated in cytoskeletal dynamics
associated with cell-cell and cell-matrix adhesions181. It interacts with many signaling
proteins implicated in mechanotransduction including p130Cas182. Whether FES plays a
direct role in mechanotransduction is unknown, but the stiffness-mediated loss of an
SH2 domain could significantly the activity of FES and its role in cytoskeletal signaling.
Similar to MIA3, variants in FES were associated with vascular disease and are eQTLs
with the risk-allele associated with reduced FES expression.
Thus, in comparison to rapid phosphorylation/enzymatic activities attributed to SH2/SH3domain proteins, stiffness-mediated splicing of these domains may represent another
layer of signaling regulation that occurs at a slower, transcriptional rate. Ultimately,
whether these SH3 and SH2 domains are important in transducing the stiffness signal
into VSMC functions will require further investigation using splicing blocking
oligonucleotides and other molecular manipulations.
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There are still many questions that can be asked of this data set. Specifically, in the
context of splicing, motif analysis of the splice sites could yield insight into the specific
splicing factors mediating stiffness-sensitive splicing. Indeed, motif analysis of
differentially included exons in contractile vs. synthetic mouse VSMCs led to the
identification of PTBP1138. In our dataset, PTBP1 was differentially expressed by
stiffness, but surprisingly, none of the PTBP1 target VSMC genes were differentially
spliced (not shown). Of note, QKI, a regulator of myocardin splicing that is upregulated in
neointimal VSMCs, was not differentially expressed by stiffness. As briefly mentioned in
Chapter 1, matrix stiffness induced phosphorylation of an SR-splicing factor, leading to
alternative splicing of fibronectin. Whether SR proteins are activated by phosphorylation
in VSMCs could not be predicted using the RNA-seq data, but may be a potential
mechanism for the observed stiffness-mediated splicing events.
Our lab recently has performed RNA-sequencing of mouse VSMCs on varying stiffness
substrates. Although there will be differences in the mouse v. human transcriptome
regulation at this complexity level, a comparison of stiffness-dependent splicing events in
this mouse VSMC dataset with our human VSMC dataset may identify conserved events
and splice-site sequences to help curate which isoforms are likely to be functional183,
especially in the case of the predicted SH3 and SH2 splicing events.

56

CHAPTER 3: REGULATORS OF THE STIFFNESS SENSITIVE TRANSCRIPTOME
Introduction
Chapter 1 gave an overview of various types of transcriptional regulators in
mechanosensing. This section will now specifically address two classes, transcription
factors and lncRNAs, and how several were historically identified and predicted to
function.
Mechanosensitive Transcription Factors
Several methods have been employed to find regulators of mechanotransduction. In
general, the methods rely on finding patterns (known and unknown) that occur more
likely than chance.
In one approach, significance of overlap is tested between the set of all observed
differentially expressed genes and the set of genes known to be regulated by a
transcription factor (gene expression signature). This is done over all known transcription
factors. Those signatures with significant overlaps are likely to explain a part of the
stimulus-mediated differential expression. This is the method employed by ingenuity
pathway analysis(QIAGEN) and DAVID159 bioinformatics tools. This approach was used
in part by the authors who identified YAP/TAZ as mechanosensitive transcription factors.
In combination with historical empirical evidence that suggested YAP/TAZ would be
stiffness-sensitive, they tested several in-house curated gene signatures for significant
overlap and found only YAP/TAZ to be significant68.
Another approach termed gene set enrichment analysis (GSEA) is a method developed
by the Broad Institute and utilizes an array of gene signatures, not limited to those
modulated by transcription factors, but also containing common transcription factor
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motifs, genes on common chromosomes, genes in a common curated cellular process
(e.g. KEGG, REACTOME), genes associated with specific cancers, mutant cells, and
genes in response to pharmaceutical compounds. Instead of an overlap, GSEA
compares a rank-ordered list of differentially expressed genes (often by some statistic,
either fold change or p-value). It then determines which gene signatures in its entire
database are over-represented at each end of the differential expression list by
calculating an enrichment score and empirically determining the p-value for significance.
This method was used to help identify a PRC2 signature in mechanosensing60.
Lastly, motif searching in promoters of differentially expressed genes is an unbiased
approach that searches for common over-represented DNA sequences. These
sequences are then matched with known DNA-binding motifs. This method is especially
useful for sets of genes that have been poorly studied and therefore has no known
signature, such as the thousands of newly identified lncRNAs, and can be done in a
targeted way with one gene or a set of genes. This general method of promoter
searching was used to identify RARG (retinoic acid receptor-G) as a stiffness-dependent
regulator of Lamin A expression171.
However, there are limitations to these methods. For example, in motif searching, while
a transcription factor binding motif may be enriched upstream of a set of genes, it is not
guaranteed that that transcription factor is active and occupying those regions. Similarly,
in gene expression signature enrichment, an enriched gene signature for factor A could
be explained by another factor(s) that also redundantly activate factor A-target genes
(i.e. multiple factors can activate the same gene). Thus, this could lead to false positives
in the enrichment process, especially if factor A is not expressed in the cell of interest
and other factors generate a factor A-like signature.
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Cell/Context Specific Transcription Factors
By extension, there may be cell-specific mechanosensitive transcription factors. As
described in Chapter 1, mechanotransduction events often require an intact contractile,
cytoskeletal network for force propagation, generation and signaling (e.g. RhoGTPases).
It would then be reasonable to suspect that transcription factors that interact with these
machineries would be stiffness-sensitive, but this is not necessarily the case. For
example, in the enrichment analyses that identified YAP/TAZ, several other
transcriptional regulators (e.g. SRF/MAL, NF-kB, and TGF-β/SMAD) were not enriched
despite their known dependence on cytoskeletal changes and mechanical stimuli68.
Indeed, there are cell/tissue-specific mechanosensitive transcription factors, such as
NKX2.5184, whose expression is mostly restricted to cardiac tissues (GTEx). And there
are relatively ubiquitous mechanosensitive transcription factors, like the aforementioned
YAP/TAZ173 and also RARG, which controls Lamin-A expression and scales with
stiffness over many human and mouse tissue171. But even these ubiquitous factors can
have differential effects based on their interacting partners. For example, YAP may
differentially interact with its DNA-binding partners (e.g. TEADs, TBX5, SMADs, RUNX2)
in different situations to activate gene programs185–187. Thus, while many common
pathways exist during mechanotransduction, different cells and different context of
stimuli may utilize different transcriptional regulators.
The Role of lncRNAs as Transcriptional Regulators
As mentioned in the introduction to Chapter 2, lncRNAs do not possess coding domains
as in protein coding genes, limiting our abilities to predict their function. By combining
multiple layers of data from high-throughput sequencing (e.g. RNA-seq, ChIP-seq,
Chromatin-conformation-capture, CHART and ChIRP-seq, RIP-seq, etc) and
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bioinformatics analyses, several roles of lncRNAs and mechanism of function have been
identified. By and large, the primarily elucidated function of lncRNAs is to regulate gene
expression, examples which will be discussed below.
Correlation analyses between lncRNAs and nearby coding genes is a commonly used
approach to predict lncRNA function at a whole transcriptome level because of its early
relative “success” (in quotations because how much failure is attributed to this strategy is
rarely reported) in identifying lncRNA function. This “guilt by association” strategy was
derived from noticing that lncRNAs and nearby protein coding genes were highly
correlated, and by using known functions of nearby coding genes, the function of an
unknown lncRNA could be roughly predicted126,188–190.
For example, the identification and elucidation of function for lincRNA-p21 resulted from
the observation that many lncRNAs were associated to p53 regulated genes. One of
those lncRNAs, lincRNA-p21, was found to be a direct target gene of p53 and
subsequent experiments determined that lincRNA-p21 mediates p53-induced apoptosis
by binding with hnRNP-K, a ribonucleoprotein, to repress transcription of survival
genes191.
Long non-coding RNAs: Mechanisms of action
Over time, more studies identified more lncRNAs that regulated gene expression, not
only of nearby genes, but also of distant genes within the same and even on other
chromosomes. This section discusses some of these mechanisms.
In one mode, lncRNAs can associate with chromatin modifying complexes to repress
expression of target genes. The lncRNA, HOTAIR was found to regulate gene
expression at hundreds of sites by binding with PRC2, a polycomb repressor complex
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protein189,192. XIST is another lncRNA that binds PRC2, and it is transcribed from one Xchromosome to transcriptionally silence the entire second X-chromosome in females to
control gene dosage. One study also found that ~20% of expressed lncRNAs were
bound to PRC2, and that silencing of select lncRNAs led to upregulation of genes known
to be PRC2 targets193. Other complexes known to associate with lncRNAs include
DNMT3b and CTCF: pRNA, a lncRNA that associates with DNMT3b to mediate DNA
methylation, and SRA, a lncRNA that binds CTCF to enhance its function to insulate
genomic regions194,195. As discussed in Chapter 1, one study showed that cyclic stretchmediated gene repression acts through PRC2 (in a cytoskeletal tension and
emerin/LINC complex dependent manner)60. Thus, it is within reason to suspect that
specific “mechanosensitive” lncRNAs may guide PRC2 to mechanosensitive coding
gene loci.
As there are many lncRNAs transcribed in relative proximity to protein coding genes,
often in enhancer regions and at low abundance, it has been proposed that some of
these lncRNAs may represent non-functional by-products of local transcriptional
processes (transcriptional noise). However, a critical early study demonstrated that
lncRNA transcripts could have enhancer-like functions (enhancer RNAs). During
keratinocyte differentiation, several lncRNAs were differentially expressed near coding
genes that were known to be involved in differentiation. SiRNA silencing of several
candidate lncRNAs were found to reduce expression of their neighboring coding genes,
demonstrating that the lncRNA transcript was functional. A series of reporter constructs
then demonstrated that it was specifically the lncRNA transcript that potentiated the
promoter activity of its target protein coding gene196.
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LncRNAs can act locally and globally. As discussed above, HOTAIR and XIST regulate
expression in hundreds of sites by associating with PRC2. Some lncRNAs also remain
locally anchored at their site of synthesis and enact their influence at distal genomic loci.
For example, HOXA locus genes, through chromosomal loops, are brought into the
proximity of the lncRNA, HOTTIP197. Even multiple gene loci on separate chromosomes
can be recruited to the lncRNA loci, as is in the case of Firre198.
Another mode of transcriptional regulation by lncRNAs is through regulation of splicing.
One mechanism was observed in NAT/Zeb2. NAT is a lncRNA that is transcribed from
the anti-sense strand of the protein coding gene Zeb2. Successful splicing of Zeb2
results in a transcript that is not normally translated, however, expression of NAT, which
overlaps the 5’ splice-site, prevents splicing of Zeb2 leading to a translatable product199.
Another was observed in the lncRNA, MALAT1, which regulates splicing by controlling
the expression, localization and activation of SR family splicing factors200
Lastly, lncRNAs have been described to act in the cytoplasm and regulate mRNA
stability and translation. For example, they have been reported to act as miRNA
sponges, or competing endogenous RNAs128,201. In this mode, the lncRNA transcript may
contain sequences that can compete and effectively sequester microRNAs that would
otherwise degrade a protein coding transcript.
The long non-coding RNA, PACER
Part of this chapter experimentally addresses the role of the lncRNA, PACER (p50associated COX-2 extragenic RNA), as a potential regulator of stiffness-mediated gene
expression. We identified PACER in a transcriptome-wide correlation analysis as a
stiffness-sensitive lncRNA whose expression is highly correlated to the nearby stiffness62

sensitive coding gene, PTGS2 (shown later in the Results section). Our lab and others
have previously found that PTGS2 is an important player in VSMC stiffness-sensing and
vascular stiffening44,217, and thus we chose to investigate PACER as a potential
upstream regulator of stiffness-mediated PTGS2 expression in VSMCs.
PACER is an 800 bp, single exon, polyadenylated lncRNA located ~200 bp upstream to
PTGS2 and is transcribed in the antisense direction relative to PTGS2. As PACER is
located in the known PTGS2 promoter region, its sequence overlaps several known
DNA-binding sites for transcription factors (e.g. NF-κB, AP1, NF-IL6, CREB,
TCF4/LEF1) known to functionally regulate PTGS2202,203. Nevertheless, PACER was
shown not to be a transcriptional by-product at the PTGS2 promoter. In human breast
epithelial cells and macrophages, PACER positively regulates PTGS2 expression by
sequestering p50 NFkB from the PTGS2 promoter. P50 NFkB when homodimerized
forms a repressive complex, but when heterodimerized with RelA/p65 NFkB (which
contains a transactivating domain) can promote transcription203. Other lncRNAs have
also been implicated in NFkB signaling, and also binding to NFkB affecting its ability to
bind DNA204. Whether PACER is functional in VSMCs and regulates stiffness-mediated
PTGS2 expression is unknown and will be addressed in this chapter.

METHODS

Unbiased motif searching
We searched predicted promoter and enhancer regions (determined by chromHMM/NIH
roadmaps)205,206 in human heart/aorta within the regions 5kb upstream of the
transcriptional start site and 1kb downstream of genes that were upregulated by stiffness
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(combined Ao and Co VSMCs). Enriched motifs were identified using the MEME suite.
Significant motifs were then matched to known transcription factor databases (JASPAR
core vertebrates v.2014207, Uniprobe207, and Jolma207) using TOMTOM208. Motifs with
known matches were then filtered, keeping matches with e-values < 1, which represents
the number of false positives expected at that point in the rank of matches per motif. We
further curated the remaining matched transcription factors for those with known
documented roles in VSMCs.
Immunofluorescence and quantification of TBX5/YAP localization
hTERT-immortalized Co VSMCs were serum starved for 48 hours then cultured on soft
and stiff hydrogels for 24 hours in SmGm-2 (Lonza). Cells were fixed in 4%
paraformaldehyde for 20 minutes at room temperature, permeabilized in PBS containing
0.5% Triton X-100, 0.11g/mL sucrose, and 0.61 mg/mL MgCl2. Cells were blocked with
1%BSA in PBS for 30 minutes. YAP antibody (mouse monoclonal IgG2a, sc-101199,
Santa Cruz) was used at 0.5 ug/mL (1:200 dilution) and incubated overnight at at 4ºC, in
1% BSA in PBS. TBX5 antibody (rabbit polyclonal) was obtained as a gift from Cathy
Hatcher (Philadelphia College of Osteopathic Medicine, PCOM, Philadelphia PA) and
previously described207. Primary incubation for TBX5 was at 0.26 ug/mL overnight at
4ºC, in 1% BSA in PBS. Alexa-488 or Alexa-568 conjugated secondary antibodies (Life
Technologies) to mouse or rabbit were used at 1:200 at room temperature for 1 hour.
Hydrogels were mounted with ProLong® Gold antifade reagent with DAPI (nuclear stain)
overnight before imaging.
An epifluorescence microscope with a 20X objective was used to image YAP, TBX5 and
DAPI signals. The area normalized intensity of TBX5 and YAP in both the nucleus and
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cytoplasm was determined using FIJI imaging software207: nuclear area delineated by
the DAPI signal, total cellular area by the boundary of each cell in the phase channel,
cytoplasmic area determined as the total cell area minus the nuclear area. The
nuclear/cytoplasmic ratio reported is the area-normalized intensity of the
nucleus/cytoplasm per cell. Approximately 20 cells were counted per experiment per
stiffness over four experiments (n = 4). Per experiment, the average nuclear/cytoplasmic
ratio of cells grown on stiff substrates are normalized to ratios from soft substrates which
was set to 1.
The correlation between YAP and TAZ localization determined using the
nuclear/cytoplasmic ratio per cell over all experiments (n = 148). Reported is the
spearman’s correlation coefficient calculated using the Hmisc library in R.
Gene Expression Validation by Quantitative RT-PCR
RNA was extracted from VSMCs using TRIzol reagent according to the manufacture’s
protocol and reverse transcribed using the High-Capacity cDNA Reverse Transcription
Kit (Life Technologies). cDNA was subjected to quantitative PCR with the following
primer-probe sets from Life Technologies: PTGS2 (Hs00153133_m1). To assay for
PACER expression, we obtained a Custom Plus Taqman Assay (Assay ID: AJWR2Q9,
Life Technologies). The primer-probe set used for 18S rRNA has been previously
described148 . Real-time qPCR results were calculated using the ddCT method with 18S
rRNA as the reference.

Assessing LncRNA Knockdown
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LncRNA knockdown was performed using locked nucleic acid GapmeRs (Exiqon).
Primary and hTERT-immortalized Co VSMCs were transfected with Lipofectamine
RNAiMAX according to the manufacturer’s protocol (Life Technologies) and with
GapmeRs targeting either a negative scramble control (50nM) or PACER (50nM) for 48
hours in Opti-MEM (Life Technologies) in 6-well plates before cells were trypsinized,
centrifuged, and replated on 18-mm hydrogels with SmGM2. Sequences for the
GapmeRs are as follows: Negative Control (5'-AACACGCTATAACGC-3'), PACER-ASO1 (5'-TTAGCGTCCCTGCAAA-3'), PACER-ASO-2 (5'-GAACTTTAAAACTCGA-3'), and
PACER-ASO-3 (5’-TGCTTAGGACCAGTAT-3’). Degree of knockdown was assessed by
quantitative RT-PCR.

Western Blot for NFkB
Serum-starved (48 hours) hTERT-immortalized Co VSMC were grown on soft and stiff
hydrogels for 24 hours in SmGm-2 (Lonza) before being washed in PBS and lysed using
the NE-PER nuclear and cytoplasmic extraction kit (Thermo Fisher). Cells on tissueculture plastic were treated with 25ng/µL TNF-alpha for 30 minutes as a control (Abcam,
ab9642). Nuclear fractions were separated via the NuPage SDS Page system
(Invitrogen, NP0322BOX). Primary antibodies used were anti-p65 NFkB (1:500, sc-372,
Santa Cruz), anti-Lamin B (1:1000, sc-365214, Santa Cruz). HRP-conjugated anti-rabbit
(1:2500, GE Healthcare Life Sciences, NA934V and NA931V) and Luminata Crescendo
Western HRP substrate (Millipore, WBLUR0100) were used to visualize the signal.
Inhibition of NFkB with BAY-11-7085
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Serum-starved (48 hours) hTERT-immortalized Co VSMC were pre-incubated with either
0.3 µM BAY-11-7085 compound (Cayman chemical, 14795) or equivalent volume of
DMSO for 30 minutes prior to trypsin treatment of cells. Cells were subsequently seeded
on soft and stiff hydrogels in the presence of either 0.3 µM BAY-11-7085 or DMSO for
24 hours in SmGm-2 before RNA was collected.
Statistical Analyses
Statistical tests for each experiment are included in the figure legends. Briefly, student’s
paired t-tests and two-way ANOVA were used in general for comparison between soft
and stiff conditions with additional perturbations. For transcriptome-wide correlation
analyses, p-values were calculated using the Hmisc library in R and the threshold for
significance was Bonferroni corrected per condition.

RESULTS
Unbiased Motif Analysis Identifies TBX5 as a novel stiffness-sensitive
transcription factor
Several approaches exist to identify transcriptional regulators that may contribute to the
observed transcriptome response to stimuli. We first chose to use unbiased motif
analysis of genes differentially expressed by stiffness. We searched for recurring motif
sequences in the promoter regions of these genes that had histone marks consistent
with active promoters or enhancers. These statistically recurring sequences were then
matched to known transcription factor motif databases and curated for transcription
factors with documented activity in VSMCs. The resulting transcription factors are listed
in Table 4. Among these factors, TBX5, a t-box transcription factor, was also identified in
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Ingenuity pathway analysis as a potential upstream regulator of the stiffness-sensitive
transcriptome (fisher’s exact test, p = 2.1e-4, Appendix 2).
We further focused on TBX5 in Co VSMCs as its expression is restricted to the lungs
and heart including the coronary arteries, but not the aorta, and is critical in coronary
artery smooth muscle cell development207,209–213. Indeed, TBX5 expression in our RNAseq was ~10-fold lower in Ao VSMC than in Co VSMCs (Figure 11A). Data from another
RNA-seq study in our lab also showed that TBX5 was further restricted to Co VSMCs
and is not expressed in Co endothelial cells (not shown). TBX5 has also been shown to
interact directly with the mechanosensitive YAP/TAZ186,214. Thus, we hypothesized that
TBX5 may be a stiffness-sensitive transcription factor in Co VSMCs that may interact
with YAP to regulate stiffness-mediated gene expression.
To determine if the nuclear/cytoplasmic localization of TBX5 was stiffness-dependent,
we cultured Co VSMCs on soft and stiff hydrogels and quantified TBX5 and YAP
subcellular localization using immunofluorescence methods as shown by others68,170,171.
Indeed, we find that nuclear localization of TBX5 was significantly increased on stiff
substrates. YAP trended toward higher nuclear localization on stiff substrates (p = 0.053,
Figure 11 B, D). YAP and TBX5 localization signals were also significantly correlated
(spearman coefficient = 0.69, Figure 11C,D), consistent with studies showing direct
interaction of YAP and TBX5 to activate their gene targets186,214. YAP/TBX5 gene targets
(BIRC5 and BCL2L1) and YAP/TEAD gene targets (ANKRD1 and CTGF) were also
increased on stiff substrates (Figure 11E). Taken together, these data suggest that
TBX5 is a stiffness-dependent transcriptional regulator in Co VSMCs and may interact
with YAP to drive stiffness-dependent gene expression.
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Table 4. VSMC-relevant transcription factor motifs enriched in stiffness-sensitive

genes using MEME/TOMTOM Suite
This table includes the top motifs that were (1) enriched in predicted promoters and
enhancers of stiffness-sensitive genes, (2) matched to known transcription factor motif
sequences, and (3) were documented to have VSMC specific functions.
Motif e-value. Statistical significance of the motif (e.g. the expected number of motifs one
would expect to find in random sequences of similar size to the input search set).
Match p-value. The probability that the match occurred by random chance according to
the null model.
Match e-value. The expected number of false positives in matches up this this point.
Match q-value. The minimum false discovery rate required to include the match.
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Figure 11. Stiffness-dependent localization of TBX5 and YAP.

(continued below)
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Figure 11. Stiffness-dependent localization of TBX5 and YAP (continued)
(A) Heatmap of the expression of TBX5 in Co and Ao VSMCs from RNA-seq
(B) Ratio of nuclear intensity (area normalized) vs. cytoplasmic intensity (area normalized) of
TBX5 and YAP in coronary VSMCs grown on stiff and soft polyacrylamide hydrogels.
Nuclear/Cytoplasmic intensity ratios were normalized to those on soft hydrogels. Significance was
determined using student’s paired t-test (* p < 0.05, $ p =0.053). Error bars are standard errors of
the mean, data was generated from measuring 148 cells (87 Stiff, 61 Soft) over n = 4 different
sets of soft and stiff hydrogels).
(C) The nuclear/cytoplasmic ratio (area normalized) per cell (n = 148) for TBX5 and YAP are
plotted on a scatterplot. TBX5 and YAP localization correlation was tested using a spearman
correlation test.
(D) Representative images of TBX5 and YAP immunofluorescence images of Co VSMCs used
for panels (A) and (B). Scale bar = 50um
(E) Expression of YAP/TBX5 and YAP/TEAD gene targets in Co VSMCs grown on soft and stiff
from the RNA-seq dataset. Y-axis per subplot are DESeq2 normalized expression values. Log2
Fold change and false discovery rate is reported for each gene target.

Transcriptome-wide correlation analysis reveals coordinated expression of
stiffness-sensitive lncRNA and stiffness-sensitive protein coding gene pairs
LncRNAs and their neighboring genes are often correlated in their expression, and
several studies have demonstrated that some lncRNAs regulate the expression of
neighboring coding genes through various mechanisms127,129,215. We asked whether the
VSMCs transcriptome-wide stiffness response may result in part by lncRNA regulation of
nearby genes. Thus, we conducted transcriptome-wide correlation analyses between all
lncRNA-gene pairs within the same chromosome. We found that the frequency of
significantly correlated lncRNA-gene pairs increased based on the proximity of the
lncRNA-gene pair (Figure 12). These significant correlations were also predominantly
positive. When comparing stiffness-sensitive to insensitive lncRNAs, stiffness-sensitive
lncRNAs exhibited a greater number of correlated gene-pairs than stiffness-insensitive
genes (Figure 13).

The top 20 most highly correlated stiffness-sensitive lncRNA-protein coding gene pairs
are presented in Table 5. The full list of significant correlations is presented in Appendix
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6. Notably, we find that the lncRNA, RP5-973M2.2 (PACER) is highly associated with
the stiffness-sensitive coding gene, PTGS2. PACER has been shown to positively
regulate PTGS2 expression in several cell types203,216, and we and others have shown
that PTGS2 is important in stiffness-sensing and contributes to vascular stiffening44,217.
Furthermore, several lncRNAs are significantly correlated to matrix and cytoskeletal
proteins that may potentially be involved in VSMC stiffness-sensing. EDIL3 (Del-1) is an
extracellular matrix protein that regulates VSMC adhesion, migration, and
proliferation218. Two nuclear membrane associated proteins are also highly correlated to
stiffness-sensitive lncRNAs. SYNE3 (aka Nesprin-3), a component of the LINC (linker of
the nucleoskeleton and cytoskeleton) complex which transmits mechanical stress from
cytoskeleton to the nucleus, may be important in the stiffness-mediated transcriptional
response61,219–221. TMPO (a.k.a lamin-associated polypeptide 2-alpha, LAP2α) is a LEMdomain containing nuclear membrane protein which binds Lamin A, much like Emerin, a
critical regulator of nuclear mechanotransduction64,222,223.
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Figure 12. Increased lncRNA-gene pair correlation with pair proximity.

(Continued below)
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Figure 12 (Continued). Correlation distributions of the top variant 1000 lncRNAs expressed Ao and Co VSMCs over different distances (A)
Scatter plot of all lncRNA-gene pair correlation scores. Each dot position represents the distance between a lncRNA and nearby gene (x-axis) and
the Spearman’s correlation coefficient (y-axis). All possible lncRNA-gene pairs within the same chromosome were correlation tested and all
lncRNAs are centered at the 0-position on the x-axis. Color of each dot represents significance after correction for multiple-hypothesis testing
(black dots are insignificant, red dots are correlations with p < 1e-5). (B) Histogram depicting the distance distribution of significantly correlated
lncRNA-gene pairs. (C) Histogram depicting the distance distribution of all correlation tested lncRNA-gene pairs. (D) Normalized distributions of
significantly correlated lncRNA-gene pairs. The number of significant lncRNA-gene pairs per bin (distance from lncRNA) is normalized by the
number of total lncRNA-gene pairs within that bin.
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Figure 13. Increased lncRNA-gene pair correlation with pair proximity and stiffness-sensitivity.
(Continued Below)
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Figure 13 (Continued). Correlation distributions of all expressed Ao and Co VSMCs lncRNAs (first column), combined Ao and Co VSMCs
stiffness-sensitive lncRNAs (second column), stiffness-insensitive lncRNAs (third column). (A) Scatter plot of all lncRNA-gene pair correlation
scores. Each dot position represents the distance between a lncRNA and nearby gene (x-axis, within a +/- 50kb range) and the Spearman’s
correlation coefficient (y-axis). All possible lncRNA-gene pairs within the same chromosome were correlation tested and all lncRNAs are centered
at the 0-position on the x-axis. Color of each dot represents significance after correction for multiple-hypothesis testing (black dots are
insignificant, red dots are correlations with p < 1e-5 for all lncRNAs, p < 4e-5 for stiffness-sensitive lncRNAs, p < 2e-5 for stiffness-insensitive
lncRNAs). (B) Histogram depicting the distance distribution of significantly correlated lncRNA-gene pairs. (C) Histogram depicting the distance
distribution of all correlation tested lncRNA-gene pairs. (D) Normalized distributions of significantly correlated lncRNA-gene pairs. The number of
significant lncRNA-gene pairs per bin (distance from lncRNA) is normalized by the number of total lncRNA-gene pairs within that bin.
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Top correlated stiffness-sensitive lncRNA-protein coding gene pairs
LncRNA
LINC00341
RP11-54O7.1
AC002116.7
RP11-800A3.4
TMPO-AS1
RP11-401P9.4
RP11-386G11.10
CTD-2269F5.1
CTB-92J24.2
CTD-2298J14.2
JHDM1D-AS1
RP11-303E16.2
RP11-110I1.12
RP5-973M2.2 (PACER)
RP11-386G11.10
RP3-462E2.3
AC009133.12
CASC15
RP1-151F17.2

Log2 FC

Distance
(kB)

PCG

Log2 FC

Spearman
R

Correlation
p-value

1.41
1.05
-1.66
2.85
-1.97
2.32
-1.97
1.17
-1.61
1.37
1.66
-1.5
-1.03
1.61
-1.97
1.78
1.18
1.63
1.4

-65.7
-13.4
-40.4
20.7
0.9
97.5
-61
-0.4
12.9
-2.7
0.2
24.3
-97.5
0.2
-3.6
45.9
30.5
71
2.9

SYNE3
SAMD11
WDR62
P2RY2
TMPO
NKD1
TUBA1C
EDIL3
ZNF726
LRFN5
JHDM1D
CENPN
H2AFX
PTGS2
TUBA1B
ALDH2
KIF22
SOX4
ATXN1

1.00
1.06
-2.17
2.26
-1.72
2.06
-2.21
1.64
-1.73
1.98
1.62
-1.56
-2.11
2.23
-2.01
1.08
-1.94
1.74
1.08

0.98
0.95
0.95
0.94
0.94
0.94
0.94
0.93
0.92
0.92
0.92
0.91
0.90
0.90
0.90
0.90
-0.89
0.89
0.89

4.00E-11
1.20E-08
2.70E-08
3.90E-08
3.90E-08
7.80E-08
1.10E-07
1.90E-07
4.30E-07
4.30E-07
4.30E-07
8.80E-07
1.70E-06
1.70E-06
2.10E-06
2.50E-06
3.60E-06
5.10E-06
5.10E-06

Table 5. Top correlated stiffness-sensitive lncRNA-protein coding gene pairs.
The top significantly correlated stiffness-sensitive lncRNAs-stiffness-sensitive protein coding gene
pairs are listed. Protein coding genes and lncRNA genes are listed along with their log 2 fold
change (log2FC > 0 represents decreased expression by stiffness). The distance between gene
pairs, Spearman’s correlation coefficient, and p-value are listed. The PACER-PTGS2 correlation
is bolded.
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Interrogation of the lncRNA, PACER as a potential regulator of nearby stiffnesssensitive protein coding genes
We further focused on the PACER-PTGS2 pair because of the importance of PTGS2 in
ECM stiffening. Studies by our lab and others have previously suggested that PTGS2 is
involved in a positive feedback stiffening mechanism whereby stiffness-mediated
suppression of PTGS2 results in enhanced collagen and fibronectin production in
VSMCs and fibroblasts leading to further ECM stiffening44,95. However, how matrix
stiffness modules PTGS2 expression is unknown. PTGS2 is a known target gene of
several transcription factors in response to several stimuli224. Recent studies in
macrophages, mammary epithelial cells, and osteosarcoma cells show that PACER
positively regulates PTGS2 expression via NFkB203,216, suggesting that the PACERPTGS2 correlation in VSMCs may underlie a functional link. NF-kB family members and
pathways were also enriched as potential transcriptional regulators of the stiffnesssensitive transcriptome (GSEA Figure 16A, pathway analysis fisher’s exact test p = 2.4e6). Specifically, RelA/p65 activity was also predicted to be inhibited by stiffness (z-score
= 2.9, fisher’s exact test p = 2.4e-3, Appendix 2). Thus, we hypothesized that stiffness
may act through PACER and NFkB to regulate stiffness-dependent PTGS2 expression
and perhaps other stiffness-sensitive protein coding genes.

We first expanded our correlation analysis of PACER with stiffness-sensitive protein
coding genes within 1Mb. We also found that PLA2G4A, which codes for cytosolic
phospholipase A2, is also correlated to PACER expression and is stiffness-sensitive in
both Ao and Co VSMCs (Figure 14A, B). Interestingly, both PLA2G4A and PTGS2,
which are located directly in cis to PACER, are key enzymes in arachidonic acid
metabolism and the synthesis of prostacyclin, which regulates stiffness-dependent ECM
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production44,45. RT-PCR confirmed that increased ECM stiffness reduced both PACER
and PTGS2 expression in primary Ao and Co VSMCs (Figure 14C).

To test whether PACER might coordinately regulate the expression of these nearby
protein coding genes, we knocked-down and over-expressed PACER in hTERTimmortalized Co VSMCs. We used three different LNA-GapmeR ASO (anti-sense
oligonucleotides) to reduce PACER expression levels grown on soft matrices to that as
in stiff matrices, but this reduction in PACER did not significantly alter PTGS2 or
PLA2G4A expression (Figure 15A). Although knockdown with PACER-ASO-2 appeared
to significantly increase expression of PLA2G4A, this may be an off-target effect as the
other two ASOs targeting PACER did not alter PLA2G4A levels. We next used a
lentiviral-based expression system (pSLIK225), to overexpress PACER. A diagram of the
expression system is in Figure 15C. Consistent with the PACER-knockdown findings,
overexpression of PACER in Co VSMCs both on soft and stiff matrices did not
significantly change PTGS2 expression (Figure 15B). However, PLA2G4A expression
was significantly higher only in VSMCs on soft substrates with PACER overexpression.

We next interrogated the role of NFkB in stiffness-mediate PACER and PTGS2
expression, as NF-kB was previously implicated in PACER-mediated regulation of
PTGS2203. Pathway analyses predict that p65/NFkB pathways are activated by soft
hydrogels, consistent with the increase in PTGS2 on soft hydrogels (Figure 14C).
Indeed, the localization of p65 (RelA), the trans-activating subunit of NFkB is stiffnessdependent. However, nuclear localization of p65 is increased on stiff hydrogels
compared to soft hydrogels (Figure 16B). This suggests that increased PTGS2
expression on soft hydrogels is independent of p65 NFkB activation. Furthermore,
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inhibition of NFkB signaling using BAY-11-7085 also did not affect PTGS2 expression on
soft hydrogels (Figure 16C). Taken together, these findings demonstrate that the
PACER-NFkB-PTGS2 axis, while discovered in epithelial cells and macrophages, may
not be intact in VSMCs.
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Figure 14. Coordinate stiffness-sensitive expression of PACER, PTGS2, and PLA2G4A
(A) UCSC Browser track view of PTGS2-PACER-PLA2G4A and their corresponding correlation in
expression (from RNAseq) with Spearman’s correlation coefficient and p-value from donormatched Ao and Co VSMCs grown on soft and stiff hydrogels. (B) PACER (RP5-973M2.2),
PTGS2 and PLA2G4A RNA-seq expression from donor-matched Ao and Co VSMCs. Log2FC
and FDR are reported above each gene (C) PACER and PTGS2 expression by quantitative-RTPCR in (Left) primary Ao VSMCs (n = 5, **** p < 0.0001) and (Right) in primary Co VSMCs (n = 7,
**** p < 0.0001). Two-way ANOVA, Holm-Sidak’s multiple comparison test.
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Figure 15. Regulation of PTGS2 and PLA2G4A by PACER
(A) PACER, PTGS2 and PLA2G4A expression by quantitative RT-PCR after PACER knockdown
using 3 different LNA-GapmeRs in hTERT-immortalized Co VSMCs cultured on soft and stiff
hydrogels (n = 4, * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001, ns not-significant, Twoway ANOVA, Holm-Sidak’s multiple comparison test).
(B) PACER, PTGS2 and PLA2G4A expression by quantitative RT-PCR after lentiviral-based
overexpression of PACER in hTERT-immortalized Co VSMCs grown on soft and stiff hydrogels (n
= 4, **** p< 0.0001, Two-way ANOVA; Holm-Sidak's multiple comparisons test).
(C) Vector map of the lentivirus-based system to overexpress PACER in VSMCs. Shown is the
region between the two LTRs.
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Figure 16. The role of NFkB in stiffness-sensitive PACER-PTGS2 expression.
(A) Enrichment Score Plot for NFKB pathways using GSEA using RNA-seq of Ao and Co VSMCs
cultured on soft and stiff hydrogels. (Left) Enrichment for NFKB using the transcription factor motif
database, C3 (Right) Enrichment for TNFalpha signaling via NFKB using the hallmark database,
H.
(B) Western blot analysis for p65 NFkB in the nuclear fraction of hTERT-immortalized Co VSMCs
grown on soft hydrogels, stiff hydrogels or tissue-culture plastic. TNF-alpha was added at
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25ng/mL for 30 minutes prior to protein collection. Lamin B was used as an internal load control.
Boxed in lanes represent different nitrocellulose membranes.
(C) RT-qPCR expression of PACER and PTGS2 from hTERT-immortalized Co VSMCs cultured
on soft and stiff hydrogels incubated with 0.3uM BAY-11-7085 for 24 hours. Student’s t-test was
performed (n =5, *** p < 0.005, ns not-significant)

DISCUSSION
In this chapter, we used several different bioinformatics approaches to identify TBX5 and
PACER as putative transcriptional regulators of matrix stiffness in VSMCs.
TBX5
Our results suggest that TBX5, as it is not expressed in Ao VSMCs, may be a Co
VSMC-specific stiffness-sensitive transcription factor. We demonstrated that TBX5
nuclear localization in Co VSMCs was increased by stiffness and highly correlated to
YAP localization, a previously identified TBX5-binding partner186,214. We also showed
that known YAP-TBX5 gene targets were up-regulated by stiffness in Co VSMCs,
consistent with the localization data. These findings only suggest a potential role for
TBX5. Further experiments in manipulating of TBX5 expression and TBX5-ChIP-qPCR
to verify promoter occupancy will be needed.
Several studies suggest potential mechanisms for how stiffness may localize TBX5. In a
series of chick model studies, TBX5 was found to bind directly to LMP4, a PDZ-LIM
domain protein that binds directly to F-actin. LMP4 has been shown to repress TBX5
activity, and in its absence, TBX5 becomes predominantly nuclear226–228. This suggests
stiffness-mediated TBX5 localization could be due to changes in the actin cytoskeleton.
Stiffness-mediated TBX5 localization in our human Co VSMCs may also be related to
changes in VSMC differentiation state. In the developing chick heart, TBX5 localization
is spatially and temporally dynamic. In undifferentiated epicardial cells (the precursor to
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coronary VSMCs that proliferate and migrate), TBX5 is predominantly nuclear. In
differentiated epicardial cells (which express VSMC differentiation markers like
calponin), TBX5 was both nuclear and cytoplasmic226. And in developed chick coronary
artery sections, TBX5 was reportedly exclusively cytoplasmic228. Perhaps, human Co
VSMCs in part become more synthetic/dedifferentiated consistent with their increased
proliferative and migratory capacity on stiff matrices (shown in Chapter 4, and prior
literature81,89).
We further suspect that TBX5 may regulate stiffness-mediated cell responses such as
proliferation/survival and migration in part through partnering with YAP, a key regulator
of growth control. In humans, mutations in TBX5 result in Holt-Oram Syndrome, which is
characterized by aplastic upper-limb malformations, congenital heart abnormalities, and
coronary artery defects213,229,230. TBX5 mutations known to cause Holt-Oram Syndrome
lead to reduced YAP/TBX5 association and reduced TBX5 transcriptional activity in
cardiomyocytes214. Furthermore, a TBX5-YAP-β-catenin complex, but not TEAD-YAP,
drives expression of BIRC5 and BCL2L1, though this study was done in cancer cells186.
We find that stiffness increases expression of BIRC5 and BCL2L1 consistent with
increased TBX5-YAP localization, but we also see increased TEAD-YAP targets,
ANKRD1 and CTGF. Whether stiffness requires TBX5 and YAP in VSMCs to induce
BIRC5/BCL2L1 expression will require further studies. Evidence in mice suggests that
TBX5 may control VSMC proliferation and migration. TBX5-knockout mice exhibit poor
coronary vasculogenesis, resulting from reduced epicardical cell proliferation and
migration into the myocardium212. As TBX5 has been predominantly interrogated in
either developing chicks and mice, or cancer cell models, whether TBX5 in mature
human Co VSMCs still control these processes will require further work.
85

Transcriptome-wide Correlation
In this study, we found that SS lncRNAs were significantly correlated with more of their
nearby genes when compared to stiffness-insensitive lncRNAs, suggesting that SS
lncRNAs may coordinate the stiffness-mediate protein coding response. We identified
several highly correlated pairs that were within 100kB of each other listed in Table 5.
Many of the protein coding genes in this list code for nucleoskeletal structures, and they,
along with their correlated lncRNA, could play a role in mechanotransduction. Only two
of the lncRNAs in this list have been previously studied, CASC15 and RP5-973M2.2
(PACER), and both have been shown to regulate coding gene expression231. However,
some of these lncRNA-coding gene pairs may be associated due to stiffness-driven local
chromosome changes, whereby clusters of genes are simultaneously co-expressed.
Thus, some of these lncRNAs may be non-functional and transcriptional noise, while
others may represent true cis-regulatory functional lncRNAs.
PACER
We hypothesized that PACER may regulate two coding genes, PTGS2 and PLA2G4A.
This was based on the highly correlated lncRNA-coding gene expression patterns,
common coding gene function in arachidonic acid/prostacyclin metabolism, and prior
reports of a cis-regulatory role of PACER on PTGS2 in three different human cell types
(mammary epithelial, macrophages, osteosarcoma lines)203,216. However, it appears that
this PACER-PTGS2 axis may not be present in human VSMCs and/or during stiffnesssensing.

This may be due to our findings that stiffness-mediated regulation of PTGS2 is NFkBindependent, while PACER regulation is NFkB-dependent. We observed that PTGS2
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expression was upregulated on soft matrices, and this effect was not reversed by
inhibition of NFkB with BAY-11-7085 (BAY-11-7085 is an inhibitor of IκBαphosphorylation, which when phosphorylated releases NFkB to become active).
Furthermore, the transactivating p65 NFkB subunit was predominantly nuclear on stiff
substrates, as seen in other studies70,232,233. Given these findings, it makes sense that
manipulation of PACER, and thus NFkB, would not have an effect on stiffness-regulated
PTGS2 expression.

Nevertheless, PACER may still have a stiffness-dependent and NFkB-dependent role by
its previously reported role in sequestering p50 NFkB. As nuclear p65 was increased by
stiffness, perhaps the simultaneous reduction in PACER may lead to less sequestered
p50, and thus influence the p50/p65 NFkB balance. It is possible that this leads to global
expression changes in stiffness-dependent NFkB gene targets (identified in our
enrichment analyses) because PACER, unlike several locally acting lncRNAs, is not
restricted to its site of transcription (~25% of its transcripts are cytoplasmic in
macrophages)203.

However, we also acknowledge that PACER’s function may be cell-type specific and
non-functional in VSMCs, despite it being expressed and stiffness-dependent. This
concept was demonstrated in a library-based lncRNA knockdown study over seven
different cell lines which identified lncRNAs that were ubiquitously expressed, but
functional in only 1 of 7 cell types127. There is also the possibility that the PACER-PTGS2
axis may be present in primary VSMCs (where the correlation analyses identified
PACER-PTGS2) and absent in hTERT-immortalized coronary VSMCs (where all the
pathway interrogation experiments were conducted). We think this is unlikely as the
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expression of PACER and PTGS2 are stiffness-dependent in both primary and hTERTimmortalized VSMCs. Thus, an RNA-seq following manipulation of PACER on soft and
stiff conditions will determine whether PACER has no function or have global
transcriptional consequences.

Then how does stiffness-regulate PTGS2? Many other transcription factor binding sites
(e.g. AP1, NF-IL6, CREB, TCF4/LEF1) are upstream (-2kb) of PTGS2 and overlap
PACER203,234, and several of these factors have been shown to regulate PTGS2
expression in human VSMCs in response to various stimuli. Our enrichment analyses for
potential upstream regulators of the stiffness-sensitive transcriptome also found CREB1
(Ingenuity, fisher’s exact test p = 2.4e-11). However, more likely, at the time of this
writing, a study showed that YAP/TAZ and TEAD mediated stiffness-repression of
PTGS2 in pulmonary artery VSMCs96. They showed that both YAP and TAZ were
sufficient and necessary for stiffness-dependent PTGS2 repression, and that this effect
was TEAD-dependent (using TEAD-binding mutants of YAP and TAZ). Furthermore,
stiffness-regulated YAP/TAZ localization is Rho-dependent, consistent with work in our
lab showing that the stiffness-mediated PTGS2 response is also dependent on Rho
activity94.
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CHAPTER 4: MALAT1, a lncRNA regulator of stiffness-sensitive VSMC functions
Introduction
This chapter focuses on MALAT1, a lncRNA that was chosen as a candidate through an
unbiased analysis of the stiffness-sensitive transcriptome in VSMCs. How MALAT1 was
determined to be the focus of this chapter will be discussed in the results section, but
this introduction serves to get the reader acquainted with the current knowledge about
MALAT1, setting the context for the hypothesis generated.
Discovery of MALAT1
MALAT1 (metastasis-associated lung adenocarcinoma transcript-1, a.k.a. NEAT2,
nuclear-enriched abundant transcript-2) was discovered in 2003, from a subtractive
hybridization screen between primary human non-small cell lung cancer tumors that had
metastasized vs. non-metastasized. MALAT1 was the most over-represented clone in
this screen, and high MALAT1 expression was highly predictive for overall survival in
lung adenocarcinomas, thus leading to its name235. Several years later, the mouse
ortholog to MALAT1 was identified in mouse hepatocellular carcinoma236, and many
reports have linked increased MALAT1 to a range of different human cancers: breast,
renal cell, cervical, colorectal and bladder cancer 237.
MALAT1 is a highly abundant, nuclear-retained transcript (hence its other name,
NEAT2) that is ubiquitously expressed in many human tissues and highly conserved in
mammals235,238. MALAT1 is a large transcript ~ 8000 bp long and can be processed into
a long (~7000 bp), nuclear-retained segment (which is often referred to as the MALAT1
transcript) and a short (61 bp), cytoplasmic segment (which is referred to as mascRNA,
MALAT1-associated small cytoplasmic RNA)239. MALAT1 has a relatively long half-life (>
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12 hrs) due to a triple helical structure on its 3’ end, compared to the ascRNA with halflife < 6 hrs. Little is known about the role of mascRNA, and most studies to date have
focused predominantly on MALAT1.
Function of MALAT1: Proliferation, Migration, and Splicing
The role of MALAT1 appears to be complex and perhaps cell and context-dependent.
Key studies regarding the role of MALAT1 will be discussed below.
Within the nucleus, MALAT1, through its two localization motifs, associate specifically
with nuclear speckles, which are sites enriched with mRNA processing and splicing
factors240. In HeLa cells, MALAT1 was found to regulate splicing programs and cell
cycle, and in MALAT1 knockdown HeLa cells, SR splicing factors (SRSF1 and SRSF3)
localization and activation were reduced leading to altered splicing in hundreds of
genes200. Furthermore, in response to serum-stimulation, MALAT1 relocates and
associates demethylated-pc2 (polycomb 2 protein, distinct from PRC2 mentioned in prior
chapters) with growth control genes within the nuclear speckle. This pc2-MALAT1
association promotes cell cycle progression by activating E2F1 and transcription of its
targets241, and knockdown of MALAT1 results in aberrant cell cycle200,241.
In contrast, one study used siRNA to knockdown MALAT1 in 10 different cell lines
(mouse and human) and found proliferation defects in some cells lines but not others242.
In zinc finger nuclease MALAT1 knockout A549s (human lung cancer cell), no difference
in splicing compared to wild-type was found. No differential splicing was seen in the
same candidate genes as those identified as differentially spliced in HeLa cells, nor in
other selected candidates243. Instead, they found that MALAT1-knockout A549 cells had
altered gene expression in metastasis-associated genes, resulting in functional defects
90

in migration and metastasis. A role for MALAT1 in migration has also been described in
HUVECs, but the knockdown of MALAT1 resulted in increased migration along with
reduced proliferation244. Lastly, these MALAT1-regulated proliferation, apoptosis, and
migration effects have been observed in many different cancers as well245. Thus,
MALAT1 appears to be critical for several cell functions in a cell specific manner.
MALAT1 as a competitive endogenous RNA
In addition to RNA processing within the nuclear speckle, MALAT1 has been proposed
to act as a competitive endogenous RNA (ceRNA), as several microRNA seed
sequences have been found in the long MALAT1 transcript. In human renal cell
carcinoma, MALAT1 and miR205 interact to control E-cadherin expression246. In mouse
myoblasts, MALAT1 coordinates with miR133 (to control SRF expression) and miR181a
(to control MYOD activity) for myogenic differentiation247,248. Furthermore, MALAT1 has
been shown to complex with Ago2249–251. These studies also suggest that MALAT1 may
not just act as a “dummy” diversion/sponge. That is, the repression in MALAT1 by a
diverted microRNA may contribute to cell phenotype as significantly as the concomitant
increase in that microRNA’s mRNA targets.
MALAT1 knockout Mice
Given that significant phenotypes have been observed in proliferation, migration, splicing
and differentiation, the in vivo role of MALAT1 was highly anticipated. At almost the
same time, three separate labs generated their own MALAT1 knockout mice and
surprisingly found no physiologic defects252–254. MALAT1 knockout mice breeding
normal, and their offspring follow expected Mendelian ratios. There were no
histopathological abnormalities assessed over 12 different organs. Staining for Ki67
(proliferation) and caspases (apoptosis) were normal. Mouse embryonic fibroblasts
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isolated from these knockouts had no altered nuclear speckle SR protein distribution or
phosphorylation. No differential splicing was observed either in brain and liver tissues.
HeLa cells were analyzed in parallel, and the aforementioned MALAT1-dependent HeLa
phenotypes were reproduced252–254. Thus, it appeared that MALAT1 was dispensible for
normal development and physiology in mice.
Role for MALAT1 during pathology
The finding that MALAT1 had no in vivo developmental phenotype was striking in
comparison to the numerous in vitro and cancer observations. It was hypothesized that
perhaps MALAT1 was important during pathological conditions, partially reconciling
these seemingly discrepant observations. Indeed, MALAT1 had a phenotypic
contribution in insult mouse models.
In a cardiotoxin-induced skeletal muscle injury model, MALAT1-knockout mice had
accelerated muscle regeneration after injury by increasing MYOD activity and myogenic
differentiation255. When MALAT1 was knocked-out in a MMTV-PyMT (mouse mammary
tumor virus) mouse model, tumors were more cystic and differentiated compared to the
solid and poorly defined tumors when MALAT1 was expressed. However, the number of
tumors was not affected. The increased tumor differentiation was also associated with
significantly fewer macro- and micro-metastasic lesions256. However, the loss of
MALAT1 did not appear to be important in pressure-overload hypertrophic
cardiomyopathy257
In the vasculature, and as relevant to this chapter, MALAT1-knockdown using antisense
oligonucleotides (ASO) in mice had reduced reperfusion after hind limb ischemia injury
compared to control ASO. MALAT1 knockout mice also had statistically reduced
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neonatal retinal vascularization, but the effect size was small. These finding were
attributed to reduced proliferation and increased migration from MALAT1-knockdown in
human umbilical vein endothelial cells244.
These studies in the MALAT1 knockout mice support the notion that the presence of
MALAT1 is functionally significant on pathologic backgrounds in vivo. How these insults
permit a role for MALAT1 is unknown, but we hypothesize that pathologic ECM stiffening
plays a role in the function of MALAT1. Indeed, many tumors, especially mammary
tumors, and hypoxic/ischemic-insults are characterized by increased ECM stiffening and
post-injury fibrosis258–262. Furthermore, as MALAT1 and stiffness have been
independently found to regulate proliferation and migration, they may be coordinating
with one another to do so. Lastly, MALAT1 appears to have cell type-dependent effects,
and while many cell types have been interrogated, the role of MALAT1 in VSMCs is
unknown. Thus, this chapter focuses on how MALAT1 was chosen as a candidate gene
representing the VSMC stiffness-sensitive response, and the role of MALAT1 in VSMCs
and matrix stiffness.

METHODS

Identification of MALAT1 as a putative regulator of stiffness-dependent functions
using Ingenuity Pathway Analysis
We used Ingenuity pathway analysis (QIAGEN) to identify lncRNAs that may underlie
the predicted functions from gene set enrichment analyses (Figure 7) because it relies
on knowledge/literature-based annotations of lncRNA function. As described in Chapter
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2, the differential gene expression lists generated by DESeq2 using combined Ao and
Co VSMC expression values were uploaded into Ingenuity Pathway Analysis (QIAGEN).
An FDR < 1e-7 and an absolute LogFC > 1 were used to select analysis-ready
molecules. Top enriched “categories” and “functions” were assessed. We identified
lncRNAs attributed to each significant category or function. These enriched lncRNAs
were then ranked based on the number of occurrences within the significant category or
functions. Only 3 lncRNAs were annotated in the ingenuity knowledge base for the
enriched categories, and only 2 lncRNAs were annotated to enriched functions.
Gene Expression Validation by Quantitative RT-PCR
RNA was extracted from VSMCs using TRIzol reagent according to the manufacture’s
protocol and reverse transcribed using the High-Capacity cDNA Reverse Transcription
Kit (Life Technologies). cDNA was subjected to quantitative PCR with the following
primer-probe sets from Life Technologies: MALAT1 (Hs00273907_s1), CCND1
(Hs00765553_m1) and CCNA1 (Hs00171105_m1). The primer-probe set used for 18S
rRNA has been previously described148 . Real-time qPCR results were calculated using
the ddCT method with 18S rRNA as the reference.

Assessing LncRNA Knockdown
LncRNA knockdown was performed using locked nucleic acid GapmeRs (Exiqon).
Primary and hTERT-immortalized Co VSMCs were transfected with Lipofectamine
RNAiMAX according to the manufacturer’s protocol (Life Technologies) and with
GapmeRs targeting either a negative scramble control (50nM) or MALAT1 (50nM) for 48
hours in Opti-MEM (Life Technologies) in 6-well plates before cells were trypsinized,
centrifuged, and replated on 18-mm hydrogels with SmGM2. Sequences for the
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GapmeRs are as follows: Negative Control (5'-AACACGCTATAACGC-3'), MALAT1ASO-1 (5'-CGTTAACTAGGCTTTA-3'), MALAT1-ASO-2 (5'-ACTAGCGTGTGGAAAG3'). Degree of knockdown was assessed by quantitative RT-PCR.

EdU Incorporation Assay
Following knockdown with GapmeRs, primary or hTERT-immortalized Co VSMCs were
plated at 10,000 cells/cm2 on 12-mm soft and stiff hydrogels in SmGM2 for 48 hours with
10µM EdU (Life Technologies). Cells were fixed in 4% Paraformaldehyde overnight. EdU
was visualized using the Click-iT EdU Imaging Kit (Life Technologies). Nuclei were
stained with DAPI. Three fields of view were counted per hydrogel to determine the
percent of EdU-positive cells relative to DAPI-stained cells. Relative EdU incorporation
was determined by normalizing all conditions to the percent EdU of the control-GapmeR
treated cells grown on soft hydrogels.

Migration Assay
For single cell migration studies, following GapmeR knockdown, Co VSMCs were plated
at 5,000 cell/cm2 on 12-mm soft and stiff hydrogels overnight. NucBlue (Life
Technologies) was then added (40µL per mL) with fresh SmGM2 30 minutes prior to the
start of the migration study. Nuclei were then imaged using fluorescence every 5-10
minutes for 5 hours. Three fields of view were captured per timepoint per condition.
Nuclei were tracked using TrackMate (ImageJ). Nuclei that were not in the field of view
for at least 4 hours were not counted. Median cell velocities, total distance (pathdependent), and total displacement (path-independent distance) were calculated.
Relative values for each parameter were determined by normalizing to the respective
values on soft hydrogels with negative control GapmeR knockdown.
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For the scratch wound assay, following GapmeR knockdown, hTERT-immortalized Co
VSMCs were plated on 12-well plates in SmGM2 at 50,000 cells/cm2 overnight to
achieve confluence. A uniform scratch was created using a 200µL pipet tip, cell debris
was washed, and fresh SmGM2 was replaced. The wound closure was assessed by
microscopy.

RESULTS
Identification of MALAT1 as a regulator of stiffness-dependent phenotypes
Most lncRNAs have no known function, and none have been implicated in the response
to ECM stiffening. To identify lncRNAs that may play a role in stiffness-mediated cellular
responses, we used unbiased enrichment analyses (Ingenuity pathway analysis) and
identified several highly enriched cellular processes in both Ao and Co VSMCs (Figure
7C): cell cycle, growth, death, motility, morphology, and RNA post-transcriptional
modifications. Among the ingenuity pathway categories and functions, MALAT1 was the
most overrepresented lncRNA annotated to these functions (Table 6, Table 7). MALAT1,
a highly conserved lncRNA, has been primarily implicated in cancer biology, and, more
recently, in endothelial cell function. Whether MALAT1 plays a role in VSMCs or in
stiffness-dependent functions is unknown.

RT-PCR validated the RNA-seq finding that matrix stiffening reduces MALAT1
expression in both Ao and Co VSMCs (Figure 17A, Figure 18A). We then focused on
using primary and hTERT-immortalized Co VSMCs. Knockdown of MALAT1 with two
different LNA-GapmeRs resulted in significant reduction in MALAT1 expression (Figure
17B, Figure 18B). Upon MALAT1 knockdown, Co VSMCs lost their elongated cell
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morphology (Figure 17C, Figure 18C). MALAT1 knockdown also reduced stiffnessdependent S-phase entry in Co VSMCs measured by EdU incorporation (Figure 17D,
Figure 18D, Figure 19A) consistent with reduced cyclin D1 and cyclin A2 expression
levels (Figure 19B). Reduced MALAT1 also decreased stiffness-induced Co VSMCs
migration speed, total distance, and displacement (Figure 17E, Figure 18E), and slowed
collective migration on a wound closure assay on stiff tissue culture plastic (Figure 19C).
Taken together, these data show that MALAT1 is a positive regulator of VSMC
proliferation and migration in response to ECM stiffness. ECM stiffness negatively
regulates MALAT1, and this may represent a homeostatic negative feedback
mechanism in which the reduction in MALAT1 limits stiffness-induced proliferation and
migration.
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Ingenuity Pathway Predicted
Categories

p-value

# Molecules

Cell Cycle

3.63E-27

538

Cellular Growth and Proliferation
Cancer
Organismal Injury and Abnormalities

4.22E-26
4.01E-24
4.01E-24

Cellular Assembly and Organization
DNA Replication, Recombin., Repair
Cell Death and Survival
Organismal Survival
Cellular Development
Post-Translational Modification
Protein Synthesis
Cellular Movement
Cellular Function and Maintenance
Cell Morphology
Tissue Development
Cardiovascular Sys Dev. and Func.
Organismal Development
Tumor Morphology
Nucleic Acid Metabolism
Small Molecule Biochemistry
Tissue Morphology
Embryonic Development
Organ Development
Organ Morphology
Skeletal and Muscular Disorders
RNA Post-Transcriptional Modification
Cardiovascular Disease

MALAT1

NEAT1

DLEU2

910
2057
2099

X
X
X

X
X

X
X

4.48E-23
4.48E-23
3.86E-22
2.88E-18
6.54E-18
1.54E-16
1.54E-16
2.71E-12
2.78E-12
2.34E-11
1.40E-10
3.20E-10
6.58E-10
5.50E-09
2.04E-08
1.01E-07
1.78E-07
2.17E-07
2.17E-07

592
454
873
608
806
80
91
575
431
528
483
331
698
203
135
113
479
412
196

X

X

X
X
X

X

2.17E-07
1.03E-06
1.47E-06
1.54E-06

153
115
78
416

X

X
X

Table 6. Identification of lncRNA regulators of stiffness-dependent cell responses
(Predicted Categorical Pathways).
Top categorical pathways identified in Ingenuity Pathway Analysis. Enrichment p-value
and number of molecules for each category are listed. An (X) denotes that the
corresponding lncRNA is represented within that canonical pathway. Only three lncRNAs
were represented for the top enriched pathways listed (i.e. no other lncRNAs were
annotated to these pathways in the ingenuity database).
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Ingenuity Pathway Predicted Functions
Proliferation of cells
Necrosis
Cell death
Apoptosis
Organismal death
Morbidity or mortality
Metastasis
Cell movement
Migration of cells
Invasion of cells
Smooth muscle tumor
Processing of RNA
Cell transformation
Organization of organelle
Formation of nucleus
Metastasis of cells
Splicing of RNA
Leiomyomatosis

p-value
4.22E-26
3.86E-22
1.72E-21
2.34E-20
2.88E-18
3.94E-18
1.63E-13
2.71E-12
2.25E-11
3.13E-10
1.06E-06
1.47E-06
2.7E-06
9.24E-06
1.21E-05
3.29E-05
3.55E-05
0.00012

MALAT1
X
X
X
X
X
X
X
X
X
X
X
X
X
X

NEAT1

X
X

X
X
X
X

Table 7. Identification of lncRNA regulators of stiffness-dependent cell responses
(Predicted Functions).
Top predicted functions identified in Ingenuity Pathway Analysis that contained lncRNAs
annotated to those functions. Enrichment p-value and for each category are listed. An
(X) denotes that the corresponding lncRNA is represented within that predicted function.
MALAT1 and NEAT1 are the only lncRNAs linked to these cellular functions in the
ingenuity database.
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Figure 17. MALAT1, a lncRNA regulator of stiffness-dependent cell functions in primary
VSMCs.
(A) Left, MALAT1 RNA-seq expression from donor-matched Ao and Co VSMCs. Right, MALAT1
expression validation by quantitative-PCR in primary Co and Ao VSMCs (n = 5 Co VSMCs, n =4
Ao VSMCs, **, p < 0.005). (B) MALAT1 knockdown using LNA-GapmeRs in primary Co VSMCs.
(C) Phase image of primary Co VSMCs cultured on tissue culture plastic for 48 hrs in SmGm2
after MALAT1 knockdown. Scale bar = 100um. (D) Primary Co VSMCs cultured on soft and stiff
hydrogels for 48 hours with serum containing EdU. Values are normalized to non-targeting control
LNA-GapmeR on soft hydrogels (n = 4, ** p<0.005; ****p<0.0001). (E) Normalized median
velocity, total distance (path-dependent) migrated, and total displacement (path-independent)
migrated in primary Co VSMCs over 5 hours. Values are normalized to velocity and distance in
non-targeting control LNA-GapmeR on soft hydrogels. (n = 4, * p<0.05, **p<0.005, Two-way
ANOVA; Holm-Sidak's multiple comparisons test).
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Figure 18. MALAT1, a lncRNA regulator of stiffness-dependent cell functions in hTERTimmortalized Co VSMCs.
(A) MALAT1 expression validation by quantitative-PCR in primary Co and Ao VSMCs (n = 7, **, p
< 0.005). (B) MALAT1 knockdown using LNA-GapmeRs in hTERT-Co VSMCs. (C) Phase image
of hTERT-Co VSMCs cultured on tissue culture plastic for 48 hours in SmGm-2 after MALAT1
knockdown. Scale bar = 100um. (D) hTERT-Co VSMCs cultured on soft and stiff hydrogels for 48
hours with serum containing EdU. Values are normalized to non-targeting control LNA-GapmeR
on soft hydrogels (n = 5, * p<0.05; ** p<0.005). (E) Normalized median velocity, total distance
(path-dependent), and total displacement (path-independent) migrated in hTERT-VSMCs over 5
hours. Values are normalized to velocity and distance in non-targeting control LNA-GapmeR on
soft hydrogels. (n=2-4, * p<0.05, Two-way ANOVA; Holm-Sidak's multiple comparisons test).
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Figure 19. MALAT1 knockdown inhibits EdU incorporation, cyclin expression and wound
closure in Co VSMCs on tissue-culture plastic (TCPS).
(A) Primary and hTERT-immortalized Co VSMCs grown on tissue culture plastic with serum
containing EdU for 48 hours following LNA-GapmeR knockdown of MALAT1 (n = 4, ** p<0.005,
*** p<0.0005).
(B) RT-PCR expression of CCND1 and CCNA1 in hTERT-immortalized Co VSMCs after
knockdown of MALAT1. Student’s t-test for LNA-control v. LNA-MALAT1-ASO1. (n = 4, ***
p<0.0005). No statistical test performed for LNA-MALAT1-ASO-2 (n=1).
(C) Phase images of the closure of the scratch wound in hTERT-immortalized Co VSMCs at 20
hours post-scratch.
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DISCUSSION
Analysis of stiffness-enriched pathways and gene sets for stiffness-sensitive lncRNAs
allowed us to identify MALAT1 as a lncRNA regulator of VSMC stiffness-dependent
proliferation and migration. To our knowledge, this is the first study implicating a role for
MALAT1 in VSMCs and its interplay with matrix stiffness. MALAT1 had previously been
linked to tumor aggressiveness in in vitro and clinical studies235,246,256,263–267. However, its
importance in vascular disease is relatively unknown, with only one study implicating
MALAT1 in endothelial cell function244. While we found that MALAT1-dependent
proliferation is similar in both VSMCs and endothelial cells, MALAT1 knockdown
enhances migration in endothelial cells while reducing migration in VSMCs.

Despite many in vitro and in vivo tumor model studies linking MALAT1 to critical cell
functions, whole-body MALAT1 knockout mice develop normally252–254. We hypothesized
that MALAT1 may regulate proliferation and migration during pathologic/abnormal
stiffening but is dispensable during physiologic/normal conditions. In support of this
stiffness-mediated dependence on MALAT1 hypothesis, our data show that MALAT1 is
necessary in VSMC proliferation and migration on stiff matrices, but is less important
under physiologically soft matrices. Most in vitro tumor cell studies interrogating MALAT1
have been conducted on culture-plastic dishes (orders of magnitude stiffer than tissue).
Whether this MALAT1-dependence would still be observed in these tumor cell types on
softer/physiologic stiffness is unknown. As the tumor microenvironment is stiffer than
normal tissue, and the increased ECM stiffness directly contributes to tumor
aggressiveness261,262,268–270, perhaps this pathologic stiffening may underlie tumor growth
and invasion dependence on MALAT1256,263,264,271. Similarly, the dependence of MALAT1
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in revascularization after ischemic injury may result from post-injury fibrosis244, while
normal vasculature development in MALAT1-knockout mice is unaffected. Thus,
vascular stiffening may lead to an aberrant dependence on MALAT1 in VSMCs.

We also find that MALAT1 expression is reduced by ECM stiffness in VSMCs and
perhaps acts in a negative feedback mechanism to limit stiffness-mediated proliferation
and migration. However, this effect may not necessarily be universal. RT-PCR validated
the stiffness-mediated reduction in MALAT1 in the donor-matched Ao and Co VSMCs
used for the RNAseq. We also validated this finding in several different donors of Ao and
Co VSMCs, but not in all donors. We believe there may be a level of variability in
VSMCs from specific donors that exhibit stiffness-mediated MALAT1 reduction while
others do not. This potential variability may reflect differences in the risk for
cardiovascular disease from vascular stiffness in various populations272,273.
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CHAPTER 5: DISCUSSION
This dissertation was motivated by arterial matrix stiffness, an important clinical
parameter for disease, but also an important mechanical property dictating cellular
behavior. We broadly addressed the question of how matrix stiffness regulated the
transcriptional programs of VSMCs, an important population in responding to and
promoting matrix stiffness. Many of the findings from this dissertation generated more
hypotheses than it answered, as is often the case in data-mining, bioinformatic
approaches. However, we had several a priori goals, including, understanding the
relative contributions of VSMC embryonic origin and matrix stiffness in regulating the
transcriptome and identifying novel transcriptional regulators of stiffness-sensing by
looking at lncRNAs and transcription factors. Working through these initial goals led us
to analyze transcriptome-wide splicing patterns and experimentally interrogate several
candidates such as MALAT1, PACER and TBX5. This chapter will put into context the
findings of the prior chapters in terms of their contributions to basic
mechanotransduction biology, clinical implications, and in each case, address important
future directions.
Basic Mechanotransduction
From a basic cellular mechanotransduction viewpoint, this dissertation provides insight
into stiffness-sensitive transcriptome characteristics likely applicable to many cellular
context, not just VSMCs. We found that stiffness-sensitive genes identified in VSMCs
are sequence conserved and tend to be expressed across multiple tissues. Thus, the
stiffness-sensitive transcriptome response, as a whole, may represent a ubiquitous
response, but whether this is necessarily true will require surveying the stiffnesssensitive response in multiple, different cell types. It would be interesting to do this
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analysis in part by integrating the several publicly available datasets of stiffnessmodulated gene expression. Of course, this has its limitations such as batch and
platform-bias (mostly microarray, few RNA-seq) effects which will need to be accounted
for, but this combined analysis may help identify ubiquitous vs. cell-specific stiffnesssensing transcriptional programs.
This is also the first study to broadly characterize, at a whole transcriptome level, the
role of stiffness in two classes of transcriptional complexity: alternative splicing and
lncRNAs. Only one study has previously described stiffness-mediated splicing in one
gene73, and no study to our knowledge has implicated lncRNAs in the stiffnessresponse. We found that stiffness-dependent lncRNA expression and alternative
splicing are cell-specific, more so than protein coding gene responses. Whether these
unique lncRNAs and splicing events confer different phenotypes in Ao and Co VSMCs
will require further work. We also identified differentially spliced genes (in both Ao and
Co VSMCs) that may be important in mechanotransduction as they are annotated in
cytoskeletal processes, but more interestingly, we found that many directly splice out
their SH3/SH2 domains due to stiffness. The implications of this were discussed in
Chapter 2.
Through bioinformatic approaches in Chapter 3, we also identified TBX5 which may be a
Co VSMC-specific, stiffness-sensitive transcription factor. Indeed, much more will need
to be studied to validate this hypothesis. A ChIP-qPCR or ChIP-seq for TBX5 will be
necessary to demonstrate differential promoter binding due to stiffness. Knockdown and
overexpression of TBX5 will also be necessary to elucidate the functional consequences
of TBX5 in Co VSMCs and whether documented-TBX5 target genes are indeed
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activated by stiffness through TBX5. Additionally, direct binding studies between TBX5
and YAP in Co VSMCs will further strengthen the role of TBX5 in stiffness-sensing.
Lastly, we focused on lncRNAs that were stiffness-sensitive in both in Ao and Co
VSMCs: MALAT1 and PACER.
We found that stiffness represses MALAT1, and that MALAT1 was necessary for
stiffness-mediated proliferation and migration. Thus, MALAT1 may exist in a feedback
loop to limit stiffness-responses. However, we suspect that MALAT1 may also contribute
to the observed stiffness-mediated alternative splicing events. In some cells (e.g. HeLa),
MALAT1 alters SR splicing factor expression and activity200. Stiffness has been shown to
phosphorylate and activate SR splicing factors 73. Furthermore, in our VSMC data, we
found that the expression of many splicing factors including some SR factors were
stiffness-sensitive, which led to the splicing term enrichment described in Chapter 2.
Thus, to determine whether MALAT1 coordinates stiffness-mediated splicing in VSMCs,
a survey of splicing events and splicing factor machinery while modulating MALAT1 in
VSMC will be required.
MALAT1 may also regulate epigenetic processes relevant to stiffness-sensing.
Epigenetic modifications in the form of histone modifications were not interrogated in this
dissertation, but are mechanosensitive, especially in response to cyclic stretch60.
MALAT1 has been shown to affect histone modifications and activity of transcriptional
machinery at growth gene loci241,255. Perhaps MALAT1 may regulate VSMC proliferation
and migration through such mechanisms. Lastly, MALAT1 has been implicated as a
competitive endogenous RNA, titrating the effects of microRNAs, some of which target
known mechanosensitive transcription factors like SRF. Recent evidence also suggest
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that microRNAs dictate stiffness-mediated responses and may even encode cellular
memory of exposure to substrate stiffness274,275. It would be interesting if MALAT1 acts
as a central regulator of mechanotransduction.
This dissertation also highlights a previously described PACER-PTGS2 axis that is intact
in several cell types, but is absent from VSMCs during pathologic stiffening. Although
PACER did not regulate PTGS2 or PLA2G4A, PACER may still regulate other genes
through its interaction with NFkB, and act as a stimulus-specific lncRNA. An RNA-seq of
VSMCs with overexpression and knockdown of PACER will be required to determine if
PACER has any transcriptome-wide consequence in VSMCs or during stiffness-sensing.
If not, PACER’s function may be cell-type-specific. Indeed, lncRNAs may be expressed
in a cell type, while having no transcriptional regulatory role in that cell127. PACERPTGS2 was identified in a transcriptome-wide correlation analysis, in which we detected
many highly correlated stiffness-sensitive lncRNA-protein coding gene pairs. How many
of these are functionally linked versus pure associations will also require further
investigation. However, the overall observation that stiffness-sensitive lncRNAs are more
correlated to surrounding genes than stiffness-insensitive genes suggest that some may
be functionally linked. Our correlation analyses also show that stiffness-sensitive genes
are often near to other stiffness-sensitive genes, suggesting that regions of
chromosome, rather than individual genes, may be stiffness-sensitive.
Clinical/Translational Implications
Altered cellular functions due to pathologic vascular matrix stiffness manifest as a clinical
predictor and risk factor for cardiovascular disease. Unlike other risk factors such as
lipids, blood glucose, and blood pressure, monitoring arterial stiffness is not yet a routine
clinical parameter. This is likely due to the relative absence and difficulty of developing
108

therapies directly targeting arterial stiffness. However, treatment of dyslipidemia,
hyperglycemia, and hypertension are often associated with reductions in arterial
stiffness. For example, angiotensin-2 signaling inhibitors (for hypertension) partially act
through anti-fibrotic effects, and AGE (advanced glycation end products)-crosslink
breakers remove non-enzymatic crosslinks due to hyperglycemia276,277. Directly treating
matrix stiffness is also difficult because it is a critical mechanical property for normal
vascular function, and in some cases act as a necessary adaptive process to withstand
changes in hemodynamic load. Unfortunately, systemic inhibition of matrix crosslinkers
like lysyl oxidase, which is critical in many tissues, can lead to adverse effects like
vascular dissection and rupture278,279. One option is targeting cellular responses to
stiffness, such as increased Rho-kinase activity. This is the basis for therapies like
fasudil, a Rho-kinase inhibitor, which has shown promise in pulmonary artery
hypertension and atherosclerosis280,281. While the side effect profile of fasudil is fairly low,
inhibition of Rho-kinase activity has been associated with systemic effects such as
hypotension282,283. Thus, an ideal therapeutic target for arterial stiffness would be one
that is dispensable during physiologic elasticity but mediates the effects of pathologic
stiffening, or one that is cell/tissue-type specific to minimize unintended consequences in
other tissues.
Our interrogation of lncRNAs, especially MALAT1, in the stiffness response may
contribute toward this goal. It appears that MALAT1 is only a critical player during
pathologic stiffness, and pharmaceutical inhibition of MALAT1 may have limited offtarget effects in non-diseased vasculature. This is supported by the finding that MALAT1
is dispensable for normal development in mice and becomes functionally relevant during
several injury models. Our findings in this dissertation support a scenario where
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pharmaceutical inhibition of MALAT1 could be used to specifically reduce pathologic
stiffness-driven VSMC proliferation and migration. To test this scenario, inhibition of
MALAT1, either by MALAT1-knockout or infusion of MALAT1 antisense oligonucleotides
during in vivo models of stiffening, such as neointimal formation after wire-injury, or an
atherosclerosis model, would be needed. It must be noted that targeting MALAT1 may
also lead to inhibition of beneficial regeneration processes such as reperfusion after
ischemia244. Furthermore, while dispensable during development and early age, it is not
known whether MALAT1-knockout mice exhibit abnormalities during later adulthood.
Mouse arteries also progressively stiffen with age and whether MALAT1-knockout mice
exhibit age-related stiffening will be interesting. Translationally, this is important as the
incidence of arterial stiffening sharply rises at older age.
We also identified several variants that were significant in GWAS for vascular diseases.
These variants were in proximity to FES and MIA3, which were both spliced by stiffness
in Ao and Co VSMCs. Understanding how the splicing of these two genes and their
function in the stiffness-response will be a new paradigm for basic mechanotransduction
biology, but it also may provide insight into why these two genes may be highly
associated with human vascular diseases. Although the variants discussed in Chapter 2
were not splicing-quantitative trait loci for FES or MIA3, a deeper analysis of the loci may
identify other variants within the same haplotype-block that may alter splice-site strength
or use of an alternative promoter and influence inclusion of a SH2/SH3 domain. If causal
variants exist for FES and MIA3, this could be clinically important for risk stratification
and developing therapeutics such as exon-skipping oligonucleotides.
Lastly, we identified several origin-specific VSMC responses that could be tissue-specific
therapeutic targets. Stiffness-driven differential splicing was highly VSMC-origin specific.
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As mentioned above, these specific splicing patterns may be amenable to exon-skipping
therapies targeting either Ao or Co VSMCs, but their role in pathogenesis will need to be
studied first. TBX5 is also a Co VSMC-specific transcription factor (although it is also
expressed in the heart, it is not expressed in other VSMCs). It may be a potential
therapeutic target with fewer off-target effects than say targeting YAP or SRF, which are
more ubiquitous. Several TBX5 animal models and human mutations in TBX5 have
provided detailed understanding of its requirement in development and cardiac
differentiation, but its role in adulthood is unknown. Inhibiting TBX5 during adulthood
could lead to cardiac dysfunction if it is required for maintenance. Thus, much about
TBX5 and whether it has a pathologic role in stiffening and coronary artery disease
needs to be established.
In summary, this dissertation integrated an engineered-stiffness culture platform with
next-generation sequencing and bioinformatics to reveal novel transcriptional properties
in the Ao and Co VSMC stiffness response, especially in lncRNA and splicing. We
explored several candidate stiffness-sensitive components and identified potential novel
mechanotranduction mechanisms. Looking forward, new classes of
transcriptomic/epigenomic properties and characteristics are being identified, and
biological data are being generated at exponential rates due to high-throughput
technology advances. Analyzing and processing these data into digestible information at
both the systems and gene-specific level will be necessary for meaningful insight and
better predictions about gene/biological function. Subsequent reductionist approaches
are still necessary to validate predictions and establish causality, and also feedback to
improve system level prediction methods.
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APPENDIX
Appendix 1. Table of Cardiovascular Disease Traits used in GWAS analyses in Chapter 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Trait Name
Abdominal aortic aneurysm
Aortic root size
Aortic stiffness
Aortic-valve calcification
Arterial stiffness
Blood pressure
Cardiovascular disease risk factors
Cardiovascular heart disease in diabetics
Carotid intima media thickness
Coronary arterial lesions in patients with Kawasaki disease
Coronary artery calcification
Coronary artery disease
Coronary artery disease or ischemic stroke
Coronary artery disease or large artery stroke
Coronary heart disease
Coronary restenosis
Coronary spasm
Diastolic blood pressure
Heart failure
Hypertension
Hypertension (young onset)
Intracranial aneurysm
Large artery stroke
Major CVD
Myocardial infarction
Myocardial infarction (early onset)
Peripheral artery disease
Pulmonary arterial hypertension (without BMPR2 mutations)
Stroke
Stroke (ischemic)
Stroke (pediatric)
Subclinical atherosclerosis traits (other)
Systolic blood pressure
Systolic blood pressure (alcohol consumption interaction)
Thoracic aortic aneurysms and dissections
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Appendix 2. Ingenuity Pathway Analysis Enriched Upstream “Transcriptional Regulators”

P-values are determined by Fisher’s Exact Test. Regulators mentioned in the text are
bolded. Only FDR<1% are shown.
Upstream
Transcriptional
Regulator
TP53

p-value of
overlap
1.43E-47

BRCA1

2.47E-08

1.95E-07

JUN

3.39E-08

2.59E-07

3.72E-45

SMAD7

5.20E-08

3.86E-07

7.83E-08

5.66E-07

FDR

E2F4

4.53E-47

5.89E-45

GATA1

E2F1

6.88E-39

5.96E-37

NKX2-3

9.79E-08

6.88E-07

CCND1

1.47E-33

9.56E-32

FOXO3

1.60E-07

1.09E-06

MYC

2.03E-33

1.06E-31

EP300

2.57E-07

1.71E-06

NUPR1

2.73E-27

1.18E-25

NFYB

2.69E-07

1.72E-06

CDKN2A

2.10E-26

7.80E-25

FOXO1

2.72E-07

1.72E-06

E2F3

2.00E-23

6.50E-22

NEUROG1

4.19E-07

2.59E-06

TBX2

5.07E-22

1.46E-20

NPAT

6.03E-07

3.65E-06

6.42E-07

3.79E-06

RB1

2.40E-21

6.24E-20

TP63

MITF

5.05E-18

1.12E-16

SP1

6.75E-07

3.90E-06

YY1

5.18E-18

1.12E-16

HIF1A

9.15E-07

5.17E-06

FOXM1

1.96E-16

3.92E-15

TAL1

9.36E-07

5.18E-06

E2F2

1.16E-14

2.15E-13

CCNE1

9.87E-07

5.24E-06

MAX

8.09E-13

1.40E-11

SIN3B

9.87E-07

5.24E-06

E2F6

2.51E-12

4.08E-11

HDAC2

1.34E-06

6.97E-06

SMARCB1

2.86E-12

4.37E-11

FOS

2.02E-06

1.03E-05

3.23E-06

1.58E-05

CREB1

2.40E-11

3.47E-10

HOXA10

E2F7

3.42E-11

4.68E-10

PAX3

3.23E-06

1.58E-05

MYCN

5.35E-11

6.96E-10

MYBL2

3.49E-06

1.68E-05

RBL1

9.31E-11

1.15E-09

CBX4

4.92E-06

2.33E-05

KDM5B

1.19E-10

1.41E-09

TCF3

8.43E-06

3.91E-05

YAP1

2.57E-10

2.91E-09

CUX1

9.69E-06

4.42E-05

NFKBIA

3.74E-10

4.05E-09

FOXP3

1.31E-05

5.87E-05

TP73

4.29E-10

4.46E-09

WT1

1.54E-05

6.79E-05

2.55E-05

1.10E-04

SMARCA4

5.86E-10

5.86E-09

HTT

HSF1

7.23E-10

6.96E-09

MEOX2

2.59E-05

1.10E-04

HNF4A

8.76E-10

8.13E-09

APBB1

5.46E-05

2.29E-04

CTNNB1

9.21E-10

8.26E-09

ATF6

5.89E-05

2.43E-04

CEBPB

2.86E-09

2.48E-08

SMARCA2

6.00E-05

2.44E-04

HDAC1

1.06E-08

8.89E-08

ATN1

7.22E-05

2.89E-04

E2F8

1.26E-08

1.02E-07

MEF2D

7.60E-05

2.99E-04
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NFYA

9.13E-05

3.54E-04

KLF4

2.02E-03

4.91E-03

H2AFX

1.17E-04

4.41E-04

IRX1

2.16E-03

5.13E-03

SMARCE1

1.17E-04

4.41E-04

PURB

2.16E-03

5.13E-03

GLI1

1.19E-04

4.42E-04

ONECUT1

2.17E-03

5.13E-03

NOTCH1

1.29E-04

4.72E-04

PDX1

2.23E-03

5.22E-03

CREBBP

1.38E-04

4.98E-04

SNAI2

2.25E-03

5.22E-03

ARNT

1.43E-04

5.09E-04

SIN3A

2.30E-03

5.29E-03

2.43E-03

5.54E-03

STAT6

1.56E-04

5.48E-04

RELA

TFEB

1.64E-04

5.69E-04

TFDP1

2.49E-03

5.63E-03

MED1

1.78E-04

6.01E-04

SMAD4

2.56E-03

5.74E-03

TWIST1

1.78E-04

6.01E-04

MYB

2.67E-03

5.93E-03

TBX5

2.09E-04

6.97E-04

HOXA9

2.75E-03

5.95E-03

REL

2.57E-04

8.46E-04

KLF2

2.76E-03

5.95E-03

AIP

2.76E-04

8.96E-04

STAT3

2.76E-03

5.95E-03

UXT

2.79E-04

8.96E-04

RUNX1

2.77E-03

5.95E-03

E2F5

2.96E-04

9.39E-04

FLI1

2.89E-03

6.16E-03

SATB1

3.90E-04

1.22E-03

PAX7

3.06E-03

6.47E-03

SQSTM1

4.09E-04

1.27E-03

NFE2L2

3.31E-03

6.94E-03

VHL

4.84E-04

1.48E-03

ID2

3.40E-03

7.04E-03

ATXN1

5.06E-04

1.53E-03

FOSL1

3.41E-03

7.04E-03

ZNF217

6.07E-04

1.81E-03

ID4

3.55E-03

7.27E-03

SRSF2

6.63E-04

1.96E-03

NOTCH3

4.46E-03

9.06E-03

RAD21

6.79E-04

1.98E-03

MYOCD

4.66E-03

9.39E-03

SMAD3

4.90E-03

9.80E-03

ERG

7.63E-04

2.20E-03

CBX3

8.99E-04

2.57E-03

CEBPA

1.05E-03

2.94E-03

EPAS1

1.05E-03

2.94E-03

HIC1

1.19E-03

3.25E-03

KLF6

1.19E-03

3.25E-03

TEAD2

1.20E-03

3.25E-03

PML

1.24E-03

3.32E-03

TFDP2

1.25E-03

3.32E-03

ID3

1.30E-03

3.41E-03

EZH2

1.37E-03

3.56E-03

CDKN2C

1.44E-03

3.67E-03

MEF2C

1.44E-03

3.67E-03

FHL2

1.48E-03

3.74E-03

MXI1

1.50E-03

3.75E-03

MNT

1.56E-03

3.86E-03

HLX

1.58E-03

3.88E-03
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STIFF Enriched
Coronary

Aortic

SOFT Enriched
Coronary

RIBOSOME
SPLICEOSOME
SYSTEMIC_LUPUS_ERYTHEMATOSUS
HUNTINGTONS_DISEASE
PARKINSONS_DISEASE
PYRIMIDINE_METABOLISM
CELL_CYCLE
OXIDATIVE_PHOSPHORYLATION
DNA_REPLICATION
PURINE_METABOLISM

RIBOSOME
SYSTEMIC_LUPUS_ERYTHEMATOSUS
SPLICEOSOME
DNA_REPLICATION
CELL_CYCLE
PYRIMIDINE_METABOLISM
PURINE_METABOLISM
HOMOLOGOUS_RECOMBINATION
HUNTINGTONS_DISEASE
MISMATCH_REPAIR

ECM_RECEPTOR_INTERACTION
LYSOSOME
FOCAL_ADHESION
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
TGF_BETA_SIGNALING_PATHWAY
PATHWAYS_IN_CANCER
GLYCOSAMINOGLYCAN_DEGRADATION
COMPLEMENT_AND_COAGULATION_CASCADES
NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION
CELL_ADHESION_MOLECULES_CAMS

ALZHEIMERS_DISEASE

PARKINSONS_DISEASE

BASAL_CELL_CARCINOMA

AMINOACYL_TRNA_BIOSYNTHESIS
RNA_POLYMERASE
HOMOLOGOUS_RECOMBINATION

RNA_POLYMERASE
BASE_EXCISION_REPAIR
NUCLEOTIDE_EXCISION_REPAIR

OOCYTE_MEIOSIS

OXIDATIVE_PHOSPHORYLATION

NUCLEOTIDE_EXCISION_REPAIR
MISMATCH_REPAIR

OOCYTE_MEIOSIS
AMINOACYL_TRNA_BIOSYNTHESIS

GLYCOLYSIS_GLUCONEOGENESIS

RNA_DEGRADATION

DILATED_CARDIOMYOPATHY
ABC_TRANSPORTERS
MAPK_SIGNALING_PATHWAY
ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDI
OMYOPATHY_ARVC
HYPERTROPHIC_CARDIOMYOPATHY_HCM
WNT_SIGNALING_PATHWAY
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDR
OITIN_SULFATE

CITRATE_CYCLE_TCA_CYCLE

P53_SIGNALING_PATHWAY

HEDGEHOG_SIGNALING_PATHWAY

ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDI
OMYOPATHY_ARVC

PROGESTERONE_MEDIATED_OOCYT
E_MATURATION

ALZHEIMERS_DISEASE

JAK_STAT_SIGNALING_PATHWAY

WNT_SIGNALING_PATHWAY

PROGESTERONE_MEDIATED_OOCYT
E_MATURATION
GLYCOLYSIS_GLUCONEOGENESIS
PATHOGENIC_ESCHERICHIA_COLI_IN
FECTION
CYSTEINE_AND_METHIONINE_METAB
OLISM
ONE_CARBON_POOL_BY_FOLATE

EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER
_PYLORI_INFECTION
PPAR_SIGNALING_PATHWAY

BASE_EXCISION_REPAIR
RNA_DEGRADATION
PATHOGENIC_ESCHERICHIA_COLI_IN
FECTION
UBIQUITIN_MEDIATED_PROTEOLYSIS
PROTEASOME

Aortic
LYSOSOME
ECM_RECEPTOR_INTERACTION
FOCAL_ADHESION
COMPLEMENT_AND_COAGULATION_CASCADES
PATHWAYS_IN_CANCER
GLYCOSAMINOGLYCAN_DEGRADATION
ABC_TRANSPORTERS
TGF_BETA_SIGNALING_PATHWAY
PROTEASOME
TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY
EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER
_PYLORI_INFECTION
HYPERTROPHIC_CARDIOMYOPATHY_HCM
INOSITOL_PHOSPHATE_METABOLISM
LEISHMANIA_INFECTION
DILATED_CARDIOMYOPATHY
PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM
PPAR_SIGNALING_PATHWAY
MAPK_SIGNALING_PATHWAY

CELL_ADHESION_MOLECULES_CAMS
NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION
JAK_STAT_SIGNALING_PATHWAY
GRAFT_VERSUS_HOST_DISEASE

Appendix 3. KEGG enriched pathways.

Enrichment performed in Gene Set Enrichment Analysis (GSEA, Broad Institute). Listed are the top 25 KEGG Terms per VSMC cell
type. Enrichment of terms are segregated by Stiff v. Soft based on the rank-order gene list for GSEA. FDR < 1% for all terms.
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STIFF Enriched
Coronary
3_UTR_MEDIATED_TRANSLATIONAL_REGULATION
ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX
AMYLOIDS
CELL_CYCLE
CELL_CYCLE_CHECKPOINTS
CELL_CYCLE_MITOTIC
CHROMOSOME_MAINTENANCE
DNA_REPAIR
DNA_REPLICATION
DNA_STRAND_ELONGATION
EXTENSION_OF_TELOMERES
G1_S_TRANSITION
G2_M_CHECKPOINTS
HIV_INFECTION
HIV_LIFE_CYCLE
INFLUENZA_LIFE_CYCLE
LATE_PHASE_OF_HIV_LIFE_CYCLE
MEIOSIS
MEIOTIC_RECOMBINATION
MEIOTIC_SYNAPSIS
METABOLISM_OF_MRNA
METABOLISM_OF_NON_CODING_RNA
METABOLISM_OF_PROTEINS
METABOLISM_OF_RNA
MITOCHONDRIAL_PROTEIN_IMPORT
MITOTIC_G1_G1_S_PHASES
MITOTIC_M_M_G1_PHASES
MITOTIC_PROMETAPHASE
MRNA_PROCESSING

Aortic
3_UTR_MEDIATED_TRANSLATIONAL_REGULATION
ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS
ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX
AMYLOIDS
CELL_CYCLE
CELL_CYCLE_MITOTIC
CHROMOSOME_MAINTENANCE
DNA_REPAIR
DNA_REPLICATION
DNA_STRAND_ELONGATION
EXTENSION_OF_TELOMERES
G1_S_SPECIFIC_TRANSCRIPTION
G1_S_TRANSITION
G2_M_CHECKPOINTS
HIV_LIFE_CYCLE
INFLUENZA_LIFE_CYCLE
LAGGING_STRAND_SYNTHESIS
LATE_PHASE_OF_HIV_LIFE_CYCLE
MEIOSIS
MEIOTIC_RECOMBINATION
MEIOTIC_SYNAPSIS
METABOLISM_OF_MRNA
METABOLISM_OF_NON_CODING_RNA
METABOLISM_OF_PROTEINS
METABOLISM_OF_RNA
MITOTIC_G1_G1_S_PHASES
MITOTIC_M_M_G1_PHASES
MITOTIC_PROMETAPHASE
MRNA_PROCESSING

STIFF Enriched (Continued)
Coronary
MRNA_SPLICING
MRNA_SPLICING_MINOR_PATHWAY
PACKAGING_OF_TELOMERE_ENDS
PEPTIDE_CHAIN_ELONGATION
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA
RESPIRATORY_ELECTRON_TRANSPORT
RNA_POL_I_PROMOTER_OPENING
RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION
RNA_POL_I_TRANSCRIPTION
S_PHASE
TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT
TELOMERE_MAINTENANCE
TRANSCRIPTION
TRANSLATION
RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMI
OSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_
NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTI
ON_COMPLEX
FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_T
HE_43S_COMPLEX
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDI
NG_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S
DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_T
HE_CENTROMERE
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_M
EMBRANE
INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION

Aortic
MRNA_SPLICING
MRNA_SPLICING_MINOR_PATHWAY
PACKAGING_OF_TELOMERE_ENDS
PEPTIDE_CHAIN_ELONGATION
PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA
RNA_POL_I_PROMOTER_OPENING
RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION
RNA_POL_I_TRANSCRIPTION
RNA_POL_II_TRANSCRIPTION
S_PHASE
SYNTHESIS_OF_DNA
TELOMERE_MAINTENANCE
TRANSCRIPTION
TRANSLATION
TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM
NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTI
ON_COMPLEX
FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_T
HE_43S_COMPLEX
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDI
NG_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S
DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_
THE_CENTROMERE
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_
MEMBRANE
INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION

Appendix 4. REACTOME Enriched Pathways (STIFF)

Enrichment performed in Gene Set Enrichment Analysis (GSEA, Broad Institute). Listed are the top Reactome Terms per VSMC cell
type. Enrichment of terms for STIFF based on the rank-order gene list for GSEA. FDR < 1% for all terms.
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SOFT Enriched
Coronary
CHONDROITIN_SULFATE_DERMATAN_SULFATE_METAB
OLISM
COLLAGEN_FORMATION
DEVELOPMENTAL_BIOLOGY
EXTRACELLULAR_MATRIX_ORGANIZATION
GENERIC_TRANSCRIPTION_PATHWAY
GLYCOSAMINOGLYCAN_METABOLISM
INTEGRIN_CELL_SURFACE_INTERACTIONS
METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS
NCAM1_INTERACTIONS
TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECUL
TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE
_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AM

Aortic
CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM
COLLAGEN_FORMATION
DIABETES_PATHWAYS
EXTRACELLULAR_MATRIX_ORGANIZATION
GENERIC_TRANSCRIPTION_PATHWAY
GLYCOSAMINOGLYCAN_METABOLISM
HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM
INNATE_IMMUNE_SYSTEM
INTEGRIN_CELL_SURFACE_INTERACTIONS
METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS
NCAM1_INTERACTIONS
TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES

Appendix 5. REACTOME Enriched Pathways (SOFT)

Enrichment performed in Gene Set Enrichment Analysis (GSEA, Broad Institute). Listed are the top Reactome Terms per VSMC cell
type. Enrichment of terms for SOFT based on the rank-order gene list for GSEA. FDR < 1% for all terms.
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LncRNA

PCG

LINC00341
RP11-54O7.1
AC002116.7
RP11-800A3.4
TMPO-AS1
RP11-401P9.4
RP11-386G11.10
CTD-2269F5.1
CTB-92J24.2
CTD-2298J14.2
JHDM1D-AS1
RP11-303E16.2
RP11-110I1.12
RP5-973M2.2
RP11-386G11.10
RP3-462E2.3
AC009133.12
CASC15
RP1-151F17.2
PRKG1-AS1
CTD-2267D19.6
RP11-800A3.4
MCM3AP-AS1
RP4-575N6.4
RP11-1114A5.4
AC005618.6
VPS9D1-AS1
RP11-443B20.1
AC005618.6
RP11-134L10.1
RP11-161H23.5
RP11-1081L13.4
RP11-366L20.3
AC005618.6
RP11-161H23.5
RP11-253M7.1
RP1-86C11.7
RP11-90B22.1
AC005618.6
AC005618.6
RP1-86C11.7
AC005618.6
DNAJC3-AS1
RP1-86C11.7
CTD-2534I21.8
RP1-43E13.2
RP1-151F17.1
AC009133.12
RP11-34D15.2
AC005618.6
RP11-243M5.1
RP11-855A2.5
RP11-123O22.1
RP1-86C11.7
RP11-632K5.3
ACVR2B-AS1
AC007743.1
AC005618.6
RP4-694A7.4
AC009133.12
GAS5-AS1
LINC01059
RP1-86C11.7
RP11-92C4.6
RP11-135L13.4

SYNE3
SAMD11
WDR62
P2RY2
TMPO
NKD1
TUBA1C
EDIL3
ZNF726
LRFN5
JHDM1D
CENPN
H2AFX
PTGS2
TUBA1B
ALDH2
KIF22
SOX4
ATXN1
DKK1
CDC6
P2RY6
C21orf58
S1PR1
ARHGEF6
PCDHGA1
SPATA33
CENPO
PCDHGA6
TMEM140
TUBA1C
TMEM86A
RP11-366L20.2
PCDHGB3
C1QL4
KIF23
HIST1H2AH
NRP1
PCDHGB4
PCDHGB7
HIST1H2BJ
PCDHGB1
DNAJC3
HIST1H2AG
KIF18B
MRTO4
ATXN1
SEZ6L2
CWF19L1
PCDHGA10
GPR133
KPNA2
RP11-180C1.1
HIST1H4I
P4HA3
ACVR2B
CCDC85A
PCDHGB2
DEPDC1
PRRT2
SERPINC1
GRAMD1B
HIST1H2BK
COL15A1
RNF112

Chr

Dist
(kB)

R

Corr pvalue

log2FC
PCG

FDR
PCG

log2FC
lncRNA

FDR
lncRNA

14
1
19
11
12
16
12
5
19
14
7
16
11
1
12
12
16
6
6
10
17
11
21
1
X
5
16
2
5
7
12
11
12
5
12
15
6
10
5
5
6
5
13
6
17
1
6
16
10
5
12
17
4
6
11
3
2
5
1
16
1
11
6
9
17

65.7
13.4
40.4
20.7
0.9
97.5
61.0
0.4
12.9
2.7
0.2
24.3
97.5
0.2
3.6
45.9
30.5
71.0
2.9
0.2
15.6
25.5
94.7
0.4
65.7
4.5
54.1
32.5
47.9
20.3
84.6
13.4
66.3
44.1
63.9
0.8
23.9
5.4
61.7
91.7
9.5
24.1
0.2
9.8
0.2
41.0
0.4
78.3
78.7
87.0
23.7
39.1
32.6
16.1
0.3
1.0
1.6
33.9
0.5
9.4
54.1
71.2
23.6
0.6
75.0

0.979
0.953
0.947
0.944
0.944
0.938
0.935
0.929
0.921
0.921
0.921
0.912
0.903
0.903
0.900
0.897
-0.891
0.885
0.885
0.879
0.876
0.876
0.874
0.874
0.871
0.865
0.862
0.859
0.856
0.853
0.853
0.847
0.847
0.841
0.841
0.841
-0.841
0.834
0.832
0.829
-0.826
0.824
0.824
-0.824
0.821
-0.821
0.818
0.815
-0.813
0.809
0.806
-0.804
0.793
-0.791
0.785
0.782
0.779
0.776
0.776
0.774
0.771
0.771
-0.771
0.767
0.765

3.98E-11
1.21E-08
2.72E-08
3.93E-08
3.93E-08
7.80E-08
1.07E-07
1.94E-07
4.32E-07
4.32E-07
4.32E-07
8.82E-07
1.68E-06
1.68E-06
2.05E-06
2.49E-06
3.62E-06
5.15E-06
5.15E-06
7.19E-06
8.44E-06
8.44E-06
9.87E-06
9.87E-06
1.15E-05
1.54E-05
1.78E-05
2.05E-05
2.34E-05
2.68E-05
2.68E-05
3.42E-05
3.47E-05
4.44E-05
4.44E-05
4.44E-05
4.44E-05
5.91E-05
6.33E-05
7.09E-05
7.92E-05
8.84E-05
8.84E-05
8.84E-05
9.84E-05
9.84E-05
1.09E-04
1.21E-04
1.27E-04
1.48E-04
1.63E-04
1.77E-04
2.46E-04
2.62E-04
3.14E-04
3.41E-04
3.72E-04
4.04E-04
4.15E-04
4.39E-04
4.77E-04
4.77E-04
4.77E-04
5.30E-04
5.60E-04

1.00
1.06
-2.17
2.26
-1.72
2.06
-2.21
1.64
-1.73
1.98
1.62
-1.56
-2.11
2.23
-2.01
1.08
-1.94
1.74
1.08
-1.21
-1.84
1.17
-1.27
-1.20
1.01
1.75
-1.01
-1.71
1.22
2.11
-2.21
2.05
1.96
1.26
-1.72
-2.64
-2.50
1.16
1.14
1.43
-2.03
1.61
1.09
-2.48
-2.49
-1.29
1.08
1.26
-1.02
1.18
-1.66
-2.19
-2.21
-2.64
1.34
1.35
-1.35
1.25
-2.56
1.07
1.01
1.27
-1.33
2.47
2.13

3.00E-08
2.81E-07
6.48E-41
2.63E-18
7.01E-29
3.23E-08
1.40E-36
4.33E-50
7.33E-14
8.04E-09
8.98E-23
6.61E-37
3.29E-48
3.17E-13
4.47E-08
2.21E-20
2.70E-54
8.08E-08
6.09E-23
5.46E-14
1.61E-23
1.68E-06
1.84E-18
1.75E-16
4.76E-11
2.83E-13
8.16E-18
1.07E-68
2.34E-10
2.61E-26
1.40E-36
8.67E-20
5.48E-08
4.72E-10
3.18E-04
7.25E-40
6.19E-36
2.83E-12
1.27E-14
2.83E-13
3.09E-48
4.46E-11
1.98E-25
3.22E-34
2.47E-40
7.84E-42
6.09E-23
8.59E-13
5.80E-27
4.15E-10
8.86E-17
8.03E-55
5.15E-18
3.58E-35
1.81E-08
2.95E-12
9.24E-13
4.98E-09
3.15E-32
1.81E-04
3.42E-03
6.68E-10
3.43E-25
5.58E-35
4.57E-10

1.41
1.05
-1.66
2.85
-1.97
2.32
-1.97
1.17
-1.61
1.37
1.66
-1.50
-1.03
1.61
-1.97
1.78
1.18
1.63
1.40
-1.03
-1.51
2.85
-1.12
-1.41
1.88
1.60
-1.93
-1.34
1.60
2.16
-2.12
1.87
1.76
1.60
-2.12
-1.76
1.84
1.91
1.60
1.60
1.84
1.60
1.03
1.84
-1.89
1.29
1.09
1.18
2.11
1.60
-1.76
2.47
-1.88
1.84
3.31
1.63
-1.14
1.60
-1.85
1.18
1.41
1.18
1.84
1.37
1.06

3.97E-11
4.44E-04
5.07E-04
1.47E-16
1.08E-23
3.47E-12
4.06E-21
4.82E-14
3.62E-06
1.14E-05
4.01E-18
2.28E-22
4.93E-07
1.28E-11
4.06E-21
6.89E-07
2.85E-05
2.35E-14
3.78E-07
5.91E-04
1.09E-08
1.47E-16
2.80E-04
1.27E-04
3.39E-07
1.55E-16
1.56E-07
2.40E-12
1.55E-16
6.02E-08
1.06E-08
4.69E-03
2.36E-04
1.55E-16
1.06E-08
1.92E-10
4.11E-06
2.42E-03
1.55E-16
1.55E-16
4.11E-06
1.55E-16
2.49E-05
4.11E-06
9.91E-06
2.97E-04
5.37E-05
2.85E-05
1.20E-03
1.55E-16
2.05E-03
1.28E-06
7.55E-06
4.11E-06
5.62E-10
4.68E-05
4.10E-05
1.55E-16
2.37E-05
2.85E-05
1.77E-04
1.57E-05
4.11E-06
3.88E-03
4.30E-03
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RP11-490M8.1
OSER1-AS1
GAS5-AS1
RP11-161H23.5
RP11-690G19.3
ANKRD10-IT1

CRIM1
JPH2
CENPL
TROAP
PLXDC1
ANKRD10

2
20
1
12
17
13

0.8
23.4
38.5
49.9
99.9
15.9

0.762
-0.756
-0.753
0.753
0.753
0.744

6.05E-04
7.06E-04
7.61E-04
7.61E-04
7.61E-04
9.48E-04

-1.01
-1.62
-1.64
-2.91
1.16
1.53

3.82E-19
2.68E-05
1.36E-26
1.49E-61
8.25E-03
1.42E-15

-1.58
1.08
1.41
-2.12
1.56
1.38

1.20E-13
2.38E-10
1.77E-04
1.06E-08
3.34E-20
9.71E-05

Appendix 6. Correlated Stiffness-sensitive lncRNA-Protein Coding Gene Pairs
Spearman’s correlation (R) for stiffness-sensitive lncRNA and protein coding genes (PCG) on the
same chromosome (Chr). The distance (Dist) between their annotated gene start coordinates is
shown in kilobases. Log2FC for LncRNA and PCG represent the combined Ao and Co VSMC
data. Log2FC and FDR calculated based on grouping soft and stiff groups together, independent
to cell-type. Only correlation p-values < 1e-5 are included.
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